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STRUCTURAL BASIS OF LMAN1 CARGO CAPTURE IN ER & RELEASE 
IN ERGIC 
  
 
VAIJAYANTI DAS 
ABSTRACT 
 
Proteins destined for secretion, after folding and the initial modification in the 
endoplasmic reticulum (ER), are transported to the ERGIC and then to Golgi stacks, 
before being sorted into their final destinations. Collectively these proteins that move 
through the secretory pathway are known as cargo proteins. Some of the soluble cargo 
proteins require cargo receptors to be efficiently packaged into vesicles exiting the 
ER. Evidence for the presence of such receptors in mammals came from the studies of 
a genetic disorder called the combined deficiency of factor V (FV) and factor VIII 
(FVIII) or F5F8D. F5F8D patients have mutations in either of the two genes – 
LMAN1 or MCFD2. LMAN1 and MCFD2 form a receptor complex that facilitates the 
ER to Golgi transport of FV and FVIII. 
Distinct binding sites for FV and FVIII exist on LMAN1 and MCFD2, but the 
specific location of these binding sites are not known. Ambiguity exists on the 
mechanism of cargo release by LMAN1 and MCFD2. Like FV and FVIII, other 
LMAN1 cargos (cathepsin C, Z and α-1 antitrypsin) are also glycosylated. Thus the 
sugar binding activity of carbohydrate recognition domain (CRD) of LMAN1 is 
presumably important for the recognition of the cargo glycoprotein.  
Using biochemical approaches we determined the locations of sugar binding 
sites and their importance in cargo binding. We successfully purified the CRD of 
vi 
 
LMAN1 using a denaturation/refolding protocol. Using isothermal titration 
calorimetry (ITC) assay, we confirmed that our purified CRD is a functional protein 
by its ability to bind to 2 calcium ions. ITC assay also provided insight on the effect 
of pH on binding ability of CRD to calcium as well as revealed the binding affinity of 
CRD towards its ligand α1-2 mannobiose. In collaboration with Dr. Saurav Misra’s 
lab, we solved the structure of mannobiose bound CRD which revealed key amino 
acids involved in ligand binding.  Mutations of these amino acids in LMAN1 were 
constructed to reconfirm their importance in sugar binding in vivo. These biochemical 
studies will provide a useful insight into the mechanism of cargo binding in the ER 
and release in the ERGIC and Golgi. 
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   CHAPTER I 
INTRODUCTION 
 
1.1 The early secretory pathway 
Up to one third of cellular proteins traverse through the secretory pathway to 
reach their final destination, including the extracellular space, the plasma membrane 
and various internal organelles. The secretory pathway is a defined route consisting of 
a series of membrane compartments. The newly synthesized proteins destined to be 
transported by the secretory pathway are translated from the poly-ribosome and sorted 
co-translationally into the lumen of the endoplasmic reticulum (ER), which 
constitutes the first component of the secretory pathway. In the ER, the nascent 
proteins are folded, oligomerized or conjugated to glycan moieties as part of their post 
translational modifications. Only the properly folded proteins exits the ER at specific 
ER exit sites and traverse through the secretory pathway.  At these ER exit sites (also 
called transitional ER), budding of the COPII (coat protein complex II) coated 
vesicles take place. Vesicles are small fluid filled sac like structures that are involved 
in cross talk between different compartments of the cell. COPII coated vesicles carry 
soluble and membrane proteins for anterograde transport (Kondylis V et al, 2009). 
2 
 
The COPII coat consists of a small GTPase Sar1 along with Sec 23/24 and 
Sec13/31 protein complexes (Baines A & Zhang B, 2007; Hughes H et al, 2008). The 
vesicle formation in vivo requires the presence of two additional proteins Sec12p and 
Sec 16p (Futai E et al, 2004; Supek F et al, 2002). Sec 12 is a guanine nucleotide 
exchange factor (GEF) for Sar1. It is because of the Sec12p that COPII assembly 
takes place only on the surface of the ER (Soderholm J et al, 2004) and it is Sec16p 
that restricts the COPII vesicle formation to the ERES (Watson P et al, 2006 ; 
Bhattacharya D & Glick B.S, 2007).  
Proteins that travel through the secretory pathway are conjointly called as 
“cargo   proteins” (Baines A & Zhang B, 2007). The cargo proteins, carried by COPII 
vesicles eventually reach the stacks of Golgi from the ER where further processing of 
the protein takes place (Kondylis V et al, 2009). The early secretory pathway (Figure 
1) refers to the transport of proteins from the ER to the Golgi (Tekaya H-B, 2004). 
But before the proteins are delivered to the Golgi apparatus, the COPII vesicles fuse 
to ER-Golgi intermediate compartment called the ERGIC (Kondylis V et al, 2009; 
Baines A & Zhang B, 2007). The supplementary transport factors and proteins that 
carry ER retrieval signals, also known as ER resident proteins, are recycled back to 
the ER (known as retrograde transport) via interaction with COPI vesicles 
(Lippincott-Schwartz  J & Liu W, 2006). This is necessary so that they can bring 
about successive series of vesicle formation and thereby anterograde protein transport.   
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1.1.1 ER-Golgi intermediate compartment (ERGIC) 
ERGIC is a tubulovesicular structure between the ER and the Golgi and it was 
earlier proposed to be the specialized domain of the ER or the cis-Golgi. Subsequent 
studies revealed that it is not continuous with the cis-Golgi or the ER and has evolved 
in parallel with the increasing complexity of the secretory pathway in higher 
eukaryotic organism. It is the site of segregation of the secretory proteins for 
anterograde transport, via packaging into COP II coated transport vesicles. Here the 
proteins are subjected to further processing and quality control (Hauri H.P et al, 2000; 
Stephens D.J & Pepperkok R, 2001).  
1.1.1.1 ERGIC is defined by LMAN1 (also known as ERGIC-53) 
LMAN1 was first identified as a novel protein in the ERGIC that was 
recognized by the monoclonal antibody G1/93 raised against purified Golgi 
membrane of Caco-2 cell line. Single and double immunoelectron microscopy 
Figure 1:Model representing the secretory, endocytic, lysosomal and vacuolar pathways in 
mammalian cells. 
The early secretory pathway is highlighted by the purple box. Traffic through the early 
secretory pathway is same for all newly synthesized proteins enroute to their final intra or 
extracellular destination. COP-coat protomer complex; ER- endoplasmic reticulum; ERGIC: 
ER-Golgi intermediate, TGN: Trans Golgi network (Modified from Bonifacino J.S et al 2004) 
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detected that this monoclonal antibody localized and labeled the tubulovesicular 
compartment lying close to cis-Golgi. The protein identified by G1/93 has a 
molecular weight of 53kD.  Experiments showed that this protein, dimerized right 
after its synthesis, followed by the formation of hexamers (Schweizer A et al, 1988). 
Because of its localization it was named as ERGIC-53. Research over the years has 
established that LMAN1 acts as cargo receptors for FV/FVIII and other glycoproteins 
but the molecular mechanism of cargo capture and release still remains to be 
determined. 
1.1.2 Cargo proteins and cargo receptors – incorporating proteins to COPII 
vesicles. 
Proteins that lack sorting signals are transported out of the ER or other cellular 
compartments by a nonspecific method called the “bulk flow. This phenomenon of 
bulk flow is observed mostly in cases when proteins are abundantly expressed. 
However the less abundant cargo proteins are sorted and concentrated before being 
recruited to the carrier vesicles in a selective manner (Martinez-Meranguez G et al, 
1999; Oprins A et al, 2001).  Studies indicate that cargo proteins in the ER that 
participate in this selective fashion of transport exhibit specific signals which help to 
recruit them into the COPII vesicles. These cargo proteins are classified into two 
types – (i) proteins that are able to bind to COPII coat directly and (ii) proteins that 
require special adapters to link them to COPII vesicles. The first group includes the 
transmembrane proteins that extend from one side of the ER membrane to the other 
side to easily reach the COPII coat proteins. These cargo proteins can act as “cargo 
receptors” for the second group which requires special receptors to link them to 
COPII vesicles (Baines A & Zhang B, 2007). Transport of cargo proteins by LMAN1 
falls in the second category where the cargos are unable to bind to vesicles directly 
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and requires LMAN1 to link them to the COPII coated vesicles. Multiple paralogs of 
COPII proteins in mammals introduce higher degree of diversity in transport vesicles, 
including tissue specific and cell specific vesicles. Hence they are able to channelize a 
variety of cargo proteins to selective transport (Baines A & Zhang B, 2007) 
The main difference between the two models of protein transport is that in the 
bulk flow model, properly folded proteins are nonspecifically packaged into COPII 
vesicles but the incompletely folded proteins are selectively retained in the ER. In the 
receptor mediated transport model, correctly folded cargo proteins are selectively 
recognized by their receptors and actively recruited to the site of vesicle budding   
(Thor F et al, 2009). 
1.1.3 Trafficking of receptor dependent soluble and transmembrane cargo 
proteins 
Soluble cargo proteins cannot interact directly with COPII coat protein. In the 
receptor-mediated transport model, trafficking of these cargo proteins are facilitated 
by specific transmembrane adapters or receptors. These receptors help packaging of 
cargo proteins into the COPII vesicles (Baines A & Zhang B, 2007). 
 First such evidence of receptor mediated transport of soluble cargo proteins 
was observed in the yeast Saccharomyces cerevisiae. In this organism, a conserved 
transmembrane protein Erv29p was essential for the packaging and transport of 
glycosylated pro-α-factor (gpαf). When Erv29p was deleted, it led to defective ER-
Golgi trafficking of gpαf (Belden W.J & Barlowe C, 2001). Further studies revealed 
the first known export signal of gpαf was recognized by Erv29p (Otte S & Barlowe C, 
2004). Two other cargo receptors have also been identified in yeast – Erv26p and 
Erv14p. Defects in these receptors led to aberrant trafficking of corresponding soluble 
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cargo. Research also showed that Emp46p and Emp47p are two homologous proteins 
in yeast that contain carbohydrate recognition domains and metal ion binding sites. 
They form a heteromeric complex in the ER and this complex is essential for the 
effective transport of Emp46p (Baines A & Zhang B, 2007). Emp47p is thus 
considered to be the cargo receptor for Emp46p. 
1.1.3.1 Cargo receptors in mammals 
So far the best studied example of cargo receptor in mammals is the LMAN1-
MCFD2 protein complex. This came into light from the finding that mutations in 
either LMAN1 or MCFD2 genes are responsible for a rare, hereditary blood 
coagulation disorder called combined deficiency of factor V and factor VIII (F5F8D), 
suggesting the potential involvement of LMAN1 and MCFD2 in selective cargo 
transport of FV and FVIII from the ER (Zhang B, 2009). The LMAN1-MCFD2 
receptor complex is believed to be the only known example to date for the trafficking 
of soluble cargo proteins. The involvement of a transmembrane component along with 
a soluble cofactor determines the uniqueness of this secretory pathway. 
1.2 Combined deficiency of factor V and factor VIII (F5F8D) 
F5F8D is an autosomal recessive blood coagulation disorder first reported in 
1954 by Oeri J et al. Cases of F5F8D has been reported throughout the world. Mostly 
associated with consanguineous marriage, F5F8D is a relatively rare disease affecting 
1:1,000,000 individuals in the general population (Spreafico M & Peyvandi F, 2008). 
However certain populations such as the Middle Eastern Jews or non-Jewish Iranians 
are at higher risk of developing this disease (Zhang B, 2009) 
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1.2.1 Phenotypic changes associated with F5F8D 
F5F8D is characterized most commonly by mild to moderate bleeding 
symptoms beginning in childhood. Bleeding symptoms include easy bruising, 
epistaxis, menorrhagia and excessive bleeding following surgery, labor or tooth 
extraction. Because of the mild bleeding symptoms, F5F8D is often underdiagnosed. 
Excessive bleeding symptoms can be controlled by the administration of fresh frozen 
plasma and recombinant FVIII (Zhang B & Ginsburg D, 2006; Spreafico M & 
Peyvandi F, 2008). 
1.2.2 Changes in the molecular level in F5F8D patients 
F5F8D patients are diagnosed with prolonged prothrombin time (PT) and 
partial thromboplastin time (PTT) [Zhang B, 2009]. In F5F8D, there is a synchronized 
reduction of plasma factor V (FV) and factor VIII (FVIII) levels. Reduction in platelet 
FV level has also been observed. Usually a dip of 5-30% of FV and FVIII activities 
takes place in F5F8D patients but in some cases it goes as low as less than 1% or as 
high as 50% (Figure 2).   
 
 
 
 
 
  
 
Figure 2. Genotype Phenotype Correlation in F5F8D: Correlation of LMAN1 and MCFD2 
with FV/FVIII levels. Short bars and numbers indicate average values. FV and FVIII levels 
are lower in F5F8D patients with MCFD2 mutations compared to patients with LMAN1 
mutations. (Represented from Zhang B et al, 2008) 
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1.2.3 Hemostasis and blood coagulation factors  
Hemostasis is a well-coordinated process to stop bleeding, regulated by the 
sequential activation of serine proteases in the coagulation cascade. This cascade of 
blood clotting factors ultimately leads to the fibrin formation. FV and FVIII are 
essential cofactors for the proteases factor X and factor IX respectively. 
1.2.3.1 Factor V 
Factor V, a 330 kDa polypeptide is synthesized primarily in hepatocytes and 
megakaryocytes and it circulates at a concentration of 20nM. The gene for FV is 
located on chromosome 1 at q21-25. Also known as the labile factor, FV is the 
inactive precursor of factor Va. FV (pro-cofactor) undergoes several post translational 
modifications – sulfation, phosphorylation and glycosylation. It is activated by 
proteases such as thrombin, factor Xa and plasmin. Thrombin cleavage is most critical 
in terms of the biological function of the molecule. It cleaves the pro-cofactor to 
generate the non-covalently linked light and heavy chain of FVa. Sulfation is required 
for efficient thrombin cleavage, activation and for full procoagulant activity. 
 
Figure 3. Schematic representation of factor V and factor VIII structures and their similarity. 
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Activated factor Va interacts with factor Xa to form the prothrombinase 
complex which in turn leads to the formation of thrombin and from thrombin, 
ultimately fibrin or the blood clot is formed. Deficiency of FV leads to an uncommon 
pathologic condition called the parahemophilia (Mann K.G & Kalafatis M, 2003).  
1.2.3.2 Factor VIII 
Also called the antihemophilic factor, FVIII is a ~ 280kDa molecule found in 
both hepatocytes and endothelial cells. The Factor VIII is structurally and functionally 
quite similar to FV. The gene for FVIII is located in X chromosome (Xq28). Factor 
VIII circulates as inactive procofactor but after limited proteolysis it gains full 
cofactor activity (Bos M & Camire R, 2010). The major role of factor VIII is the 
conversion of factor X to its activated form Xa by acting as a cofactor for factor IX in 
the presence of calcium ion and phospholipids. In blood, it mostly exists as a stable 
complex with von Willebrand factor. After cleavage by thrombin, it dissociates from 
the complex and takes part in the coagulation cascade. Normal plasma levels of factor 
VIII range from 50% to 150%. 
Deficiency in factor VIII leads to hemophilia A, a hereditary bleeding disorder 
affecting about 1 in every 5000 males in Unites States. Hemophilia A represents about 
80% of the total hemophilia cases. FVIII level below 1% is a bleeding disorder often 
associated with “severe bleeding episodes” that can lead to severe consequences if left 
untreated (Camire R, 2009).  
FV and FVIII share similar domain structures – three sets of domain A, one B 
domain and two sets of C domain (Figure 3). Sequence identity between the A and C 
domains of these two coagulation factors is very high. B domains of FV and FVIII 
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share little sequence homology but are both heavily glycosylated with 9 potential 
glycosylation sites in the heavy chain (Mann K.G & Kalafatis M, 2003).  
1.2.4 Genetic Predisposition of F5F8D 
Genetic studies like homozygosity mapping and positional cloning on patients 
with F5F8D identified mutations in either of the 2 genes LMAN1 (also known as 
ERGIC 53 or p53) or MCFD2. In 70% cases it is caused by mutations in LMAN1 and 
in 30% cases it is caused by mutations in MCFD2 (Zhang B et al, 2006). F5F8D 
caused by LMAN1 mutation is clinically indistinguishable from the disease caused by 
mutation in MCFD2, though it has been generally noticed that patients with MCFD2 
mutation has lower FV and FVIII levels (Figure 2). However from the FV and FVIII 
levels, it cannot be predicted which kind of mutation a patient would have. 
1.2.4.1 Mutations in LMAN1 
So far 32 mutations have been identified in LMAN1 gene, spanning its 13 
exons that lead to F5F8D. The majority of mutations are null mutations resulting from 
normally frameshift or non-sense mutations that produce shortened protein differing 
in function from the normal LMAN1. One F5F8D patient showed no mutations in the 
exon or exon-intron junction but had mutation in the regulatory region of the gene 
(Zhang B et al, 2006; 2008). Two missense mutations in LMAN1 are known – one 
substitutes methionine with threonine thereby abolishing protein translation and the 
second one changes arginine to cysteine (Nufer O et al, 2003). This conversion of 
arginine to cysteine leads to the production of an unstable protein (Zhang B, 2006). 
The mutations occurring in LMAN1 are shown in Figure 4. 
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. 
1.2.4.2 Mutations in MCFD2 
There were 17 mutations known to occur in MCFD2 that led to F5F8D. Nine 
of these are deletion or splicing mutations that resulted in shortened protein products 
and seven were missense mutations which changed conserved amino acids (Zhang B 
2009; Zhang B et al, 2011). The other kind of alteration was a non-sense mutation that 
deletes 8.5kb in the promoter region of the gene along with the last three amino acids 
of MCFD2 thereby disturbing the protein structure (Nyfeler B et al, 2007). MCFD2 
mutations that cause F5F8D are shown in Figure 5. 
 
Figure 4. Mutations found in LMAN1gene (Represented from Spreafico M et al, 2008) 
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1.3 Lectin Mannose-binding 1 (LMAN1)  
LMAN1 is a nonglycosylated, type I single spanning transmembrane protein, 
of molecular weight 53kD. It cycles between the ER and the ERGIC/cis-Golgi. 
LMAN1 serves as the indicator protein to define organelle boundaries and has been 
established as a marker for the ER-Golgi intermediate compartment (ERGIC). 
LMAN1 is conserved across species, from vertebrates such as human and mouse to 
invertebrates such as Xenopus laevis and Saccharomyces cerevisiae (Hauri H-P et al, 
2000). 
Figure 5. Mutation in MCFD2 gene (Represented from Spreafico M et al, 2008) 
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Human LMAN1 gene is localized in the long arm of chromosome 18 (18q21.3-
18q22). The mRNA coding for this protein is 2768 bp with 13 exons, of varying 
lengths ranging from 59bp (exon 7) to 1244bp (exon13). Exon 13 is the longest one 
but it codes for only amino acids 499-510 and the remaining more than 1200bp lies in 
the 3’ UTR (Nichols W.C et al, 1999). 
 LMAN1 is ubiquitously expressed in all tissue types but generally has higher 
expression in secretory cell types (Zhang B et al, 2011). Within the cell, LMAN1 
either exists as six disulfide linked monomers or three disulfide linked dimers joined 
noncovalently forming a hexamer (Neve E.P et al, 2005). Endogenous LMAN1 exist 
in a Ca2+ dependent complex with MCFD2 in a 1:1 stoichiometry. However, MCFD2 
is not necessary for oligomerization of LMAN1 (Zhang B et al, 2005).  
1.3.1 Structure of LMAN1 
Human LMAN1 consists of about 510 amino acids, which includes an N 
terminal signal sequence of 30 amino acids residues, a carbohydrate recognition 
domain (CRD) of about 240 residues a stalk region of 210 amino acids, a 
transmembrane domain of 18 residues and a short cytoplasmic domain of 12 residues 
(Figure 6 & Figure 7). The stalk region of LMAN1 consists of a series of four α 
helices that are believed to form a coiled coil domain with two conserved cysteine 
residues, Cys 466 and Cys 475.  
 
 
Figure 6. Different domains of LMAN1 (Zhang B, 2009) 
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Each domain of LMAN1 has their respective functions which are quite diverse from 
one another and is necessary for the proper functioning of the protein molecule 
(Figure 7). 
 
 
 
1.3.1.1 Domains of LMAN1 
The different domains of LMAN1 are as follows: 
i) Carbohydrate Recognition Domain (CRD) of LMAN1  
As the name indicates, it is that part of LMAN1 which interacts with sugar 
molecules of the cargo proteins. It is the ~200 residue segment in the luminal domain 
and bears homology with the CRD of various leguminous plant lectins. 
A. Similarity to leguminous lectins 
Studies revealed sequence homologies of LMAN1 (19-24%) with leguminous 
lectins (Itin C et al, 1996). The core structure shared the same basic architecture as the 
leguminous lectins. Leguminous lectins (Latin: lectus means “to gather” or “select”) 
Figure 7. Detailed representation of the different domains of human LMAN1: S-
Signal peptide, CRD-carbohydrate recognition domain, TMD-transmembrane 
domain and CD-cytoplasmic domain (Zhang Y.C et al, 2009) 
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are a class of proteins that bind to sugar (or carbohydrate) binding proteins without 
modifying them, unlike glycoproteins which itself contain covalently linked sugars. 
Immense studies at the molecular and structural level on this class of lectin revealed 
that they were synthesized within the secretory organelles of the plant and mostly 
homo-oligomerized to form dimers or tetramers. These plant lectins were capable of 
agglutinating cells and bound to a variety of glycoproteins having varied carbohydrate 
structure. Concanavalin A was the first plant lectin to be crystallized and was found to 
bind and precipitate polysaccharides like glycogen and starch (Cummings R.D et al, 
1999).  
Usually leguminous lectins were metalloproteins that bind to metals ions Ca2+, 
Mg2+ or Mn2+. It was observed that if these metal ions in leguminous lectins were 
chelated with reagents like EDTA, lectins failed to bind to the glycocojugates. These 
lectins had common consensus sequences which helped in their easy identification 
(Figure 8). They had antiparallel beta pleated sheets and a carbohydrate binding 
pocket consisting of two cavities that worked in coordination with one another. In one 
cavity lied the metal ions and the other had the monosaccharide. In between these two 
cavities, were conserved residues – an aspartate (Asp/D) and an Asparagine (Asn/N). 
These residues interacted with the metal ions and also were hydrogen bonded to the 
monosaccharide. The metal ions were believed to serve a pivotal role in orienting the 
conserved residues as well as maintain their proper distance from the monosaccharide 
(Itin C et al, 1996).  
LMAN1 exhibited all these properties of a leguminous lectin hence it was 
considered to be a putative new class of animal L-type lectins associated with the 
secretory pathway. Like leguminous lectins, LMAN1 is Ca2+ dependent and mutation 
in the conserved residues of asparagine and aspartate in LMAN1 abolished its ability 
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to bind to mannose column. Hence, it was predicted that these two residues might be 
important for the lectin activity of LMAN1. This was also based on the fact that 
LMAN1 bore similarity to VIP-36 which is a membrane protein and was found to 
bind to mannose in vivo (Itin C et al, 1996).  
 
 
 
B. Crystal structure of the CRD of LMAN1 
Crystal structure of the carbohydrate recognition domain of rat p58 which is 
the homologue for human LMAN1 was first solved by Velloso et al in 2002. They 
observed that the CRD was bulbous in shape, had one concave and one convex β- 
sheet packed into a β sandwich and the folds and ligand binding sites were similar to 
leguminous lectins. Though the oligomeric form of LMAN1/p58 binds to mannose 
monosaccharide but mannose was not the correct ligand for LMAN1. It was believed 
to bind to Man9 of glycoproteins (Velloso L.M et al, 2002). 
Figure 8. Shared sequences of two typical lectins – lima bean lectin and soybean 
agglutinin (Cummings R et al ,1999).  
17 
 
From the sequence homology (Figure 9), it was seen that conserved asparagine 
and aspartate residues in p58 - N164 and D129 corresponds to N156 and D121 of 
human LMAN1 and these might be crucial for binding to mannose. The other 
conserved residues of LMAN1 are Trp51, Trp78, Trp110, Trp128, glycines in loop 
between β strands, two disulfide bonded cysteines (Cys 466 and Cys 475) and proline 
(Velloso L.M et al, 2002). However the crystal structure of the CRD that was solved 
first was without the calcium ion and it was known that the proper functioning of 
LMAN1 requires the presence of this metal ion. Hence, Velloso later on solved the 
crystal structure of the CRD in presence of Ca2+ (Figure 10). 
 
 Figure 9. Sequence alignment of rat LMAN1(p58) and VIP-36 like CRD. Secondary 
structure elements are shown as arrows and rectangles, representing β strands, dashed line 
are the disordered regions. Blue arrowheads are the splice sites (Velloso L.M et al, 2002). 
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Leguminous lectins that bound to two calcium ions contained two metal ion 
binding sites –S1 and S2. In studies that were carried out on Concanavalin A, it was 
observed that initially the metal ion binds to site S1 and then to the second site S2. 
This binding of metal ions caused large structural changes in the CRD resulting in an 
alteration from the unlocked to the locked form of the protein. This step was 
considered crucial for carbohydrate binding (Figure 10). The crystal structure of the 
CRD of p58 behaved likewise. (Velloso L.M et al, 2003). 
When the crystal of the CRD of p58 was grown in the presence of Ca2+, it 
revealed well defined electron density compared to the calcium free form where the 
residues were disordered. Large conformational changes were observed between the 
calcium bound crystals from the calcium free form. These changes primarily involved 
the two regions of the protein that contain all the calcium ion coordinating residues. 
These two major sites were – (i) loop between residues 161 and 172 (referred as 
loop1) and (ii) loop between residues 179 and 193 (referred as loop 2); most 
prominent change was observed in the residue N164  (Figure 10). The crystal 
structure of the CRD in presence of Ca2+ ions showed the presence of a site similar to 
S2 of leguminous lectins and it was called M2. Despite the similarity between 
LMAN1 and the leguminous lectins, electron density map showed the absence of the 
S1 site in LMAN1. Mutagenesis studies at the histidine and glutamate residues 
present in the side chain of S1 also confirmed the absence. But it was observed that 
there is another site, referred as M1, located close to the loop between 161 and 172 
which represented a metal binding site (Velloso L.M et al, 2003). 
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C. Comparison between rat p58/LMAN1 and Isolectin 1  
 Isolectin 1 is a leguminous lectin that was best illustrated and most similar to 
LMAN1 structurally. When LMAN1 was superposed on Isolectin 1, it was observed 
that the site M2 corresponded to the site S2 of leguminous lectin and they were only 
1Ǻ apart. But the site M1 did not correspond to the site S1 as their positions were 6.4 
Ǻ apart. Residues Asp160, Asn 164, Phe162 and two water molecules that acted as 
calcium ion ligands were identical in p58/LMAN1, Concanavalin A and Isolectin 1 
(Velloso L.M et al, 2003).  
Figure 10. (a)Crystal Structure of CRD of Rat LMAN1 showing the location of bound 
Calcium ions (pink spheres).  
(b) Loops changing conformation upon binding to metal ions (shown in green) (Velloso 
L.M et al, 2003). 
 
20 
 
 
 
The ligand binding sites of leguminous lectins were highly conserved across 
different proteins. A model (Figure 11) was proposed comparing the ligand binding 
sites of octasaccharide complex of Isolectin 1 and p58/LMAN1. The three different 
ligands used in the modeling study were Man(α1-3)4, Man(β1-3)3 and Man(α1-6)4. 
According to the model, the ligand binding sites for one ligand Man(α1-3)4 were 
remarkably similar between Isolectin 1 and p58/LMAN1. This was the only mannose 
that hydrogen bonded to Isolectin 1. Except Gly99, all other hydrogen binding 
residues for this ligand had their counterparts in LMAN1 and were identical in nature 
and in similar position. Gly99 of Isolectin 1 was the only residue that did not have a 
counterpart in LMAN1 but was present in Isolectin 1 and Concanavalin A. Absence 
of this residue in LMAN1 rendered it with a more open ligand binding site compared 
to leguminous lectins (Velloso L.M et al, 2003). 
The main difference between LMAN1 and Isolectin 1 was their localization. 
LMAN1 is mostly restricted to ER and ERGIC but Isolectin 1 is present in the 
Figure 11. Comparison of the ligand binding sites of Isolectin 1 and p58/ rat LMAN1. 
Residues hydrogen bonding to the Man (α1-3)4 residue of Isolectin-1 are shown in light 
blue and their counterparts in p58 are shown in green (Represented from Velloso L.M et al, 
2003) 
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extracellular space. Because of this difference in localization, the ligands for these 
two kinds of lectins were also different. Isolectin 1 and other leguminous lectins 
recognize complex sugar structures that were extensively modified in the stacks of 
Golgi but LMAN1 recognizes Man8(GlcNAc)2 as ligand. LMAN1 ligand differed 
from the complex sugar structures recognized by leguminous lectins in the number of 
branches as well the terminal sugar residues. When protein exit ER and enter the 
stacks of Golgi for further modification, the sugars are all mannose and carries three 
branches but when the protein exits the Golgi where it has undergone further 
modification, proteins carry only two branches with N-acetylglucosamine, galactose 
or sialic acid at the termini. Probably because LMAN1 has more exposed ligand 
binding site, it is able to connect with more branched structures. This may be a 
plausible reason for the M1 site in LMAN1 to be positioned differently from the S1 
site in leguminous lectins (Velloso L.M et al, 2003).  
 ii) LMAN1 stalk 
As shown in Figure 7, the stalk consisted of a series of four α helices expected 
to form a coiled coil and two conserved cysteine residues of LMAN1, Cys 466 and 
Cys 475 located close to the transmembrane domain. These conserved residues were 
initially believed to be critical for dimerization and hexamerization of LMAN1 
(Figure 12). But further research revealed that the conserved cysteines might not be 
crucial for oligomerization of the protein. It was stated that the helical part of LMAN1 
was essential for hexamerization of the protein and LMAN1 existed as SDS sensitive 
and SDS resistant hexamers (Neve E et al, 2005). However, the role of cysteine 
residues is still unclear.  
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iii) Transmembrane domain (TMD) of LMAN1  
TMD of LMAN1 consists of 18 amino acids. This length of TMD affects ER 
retention. Experiments showed that an optimum of 21 amino acids is necessary for 
efficient ER exit but the length of TMD of LMAN1 is sub optimal. However, TMD 
contains a motif of three residues F484/Q488/Y498. Q488 is unique for human LMAN1. 
This motif may also contribute to the hexamerization of LMAN1 (Nufer O et al. 
2003). 
iv) Cytoplasmic domain of LMAN1  
The cytoplasmic domain of LMAN1 with amino acid sequence 
RSQQEAAAKKFF plays the most important role in the correct targeting of the 
protein in the ER-ERGIC-Golgi recycling pathway. The last four amino acid residues 
of the above mentioned sequence acts as determinants for this function. The double 
lysine (KK) residue act as ER retention and retrieval signal via interaction with COPI 
Hexamerized LMAN1 
MCFD2 
Figure 12. The hexameric form (gray cylinders) of LMAN1 bound to MCFD2 (Baines A & 
Zhang B, 2007) 
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and thereby leading to efficient endocytosis of LMAN1 from the cell surface when it 
is overexpressed (Schindler R et al, 1993). The double phenylalanine (FF) residue is 
important for ER exit mechanism via interaction with COPII. As a result, it 
considerably weakens the ER retention signal and at a steady state there is a 
significant level of the LMAN1 localized outside ER (Zhang Y.C et al, 2009). 
1.3.2 LMAN1 – A potential ER exit sorting receptor  
Any sorting receptor has to be a transmembrane protein that has a cytoplasmic 
domain interacting with COPI and COPII proteins and an ER luminal domain that 
interacts with cargo. LMAN1 structure satisfies all requirements for a sorting receptor 
with its CRD, cytoplasmic ER exit and retrieval signals and transmembrane domain 
(Itin C et al, 1996). LMAN1 has a long half-life of several days. This may contribute 
to its function of a transport receptor for glycoproteins (Zhang Y. C, 2009).  
1.3.3 Cargo recognition and binding by LMAN1 
LMAN1 with MCFD2 form a receptor complex and helps in the transport and 
synthesis of blood coagulation factor V and factor VIII. Other potential cargos for 
LMAN1 are the lysosomal proteins cathepsin C, cathepsin Z and α-antitrypsin 
(Baines A & Zhang B, 2007; Nyfeler B et al, 2008).  
The cargos for LMAN1 –FV, FVIII, Cat C, Cat Z or α-antitrypsin, are all 
glycoproteins. They undergo trimming and processing at the early secretory pathway 
in order to be transported by LMAN1. This trimming and processing that takes place 
makes all proteins structurally and functionally diverse. It is the heterogeneity of the 
glycan moieties in the glycoproteins that renders them this diversity. They differ in 
the sugar composition, number and size of branches in the sugar tree and this 
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distinction is observed across cell types, tissues and species. However, the glycan 
moiety that conjugates to the nascent polypeptide right after its synthesis in the ER is 
homogenous and relatively simple. This glycan moiety is called “core glycan” and 
this does not make the glycoproteins much different from one another (Figure 13) 
(Helenius A et al, 2001).   
When these glycoproteins reach the medial stacks of Golgi, they undergo 
extensive alteration by non-uniform trimming and processing. It is the terminal 
glycosylation that takes place in the vertebrate and plant Golgi complex which 
introduces significant heterogeneity in these glycoproteins. As a result of this switch 
from structural uniformity in the ER to the gain of diversity in the Golgi complex, 
there occurs a change in glycan function. These glycan moieties conjugated to the 
proteins plays a role in promoting protein folding, quality control and sorting events 
(Figure 13). The complex sugar chains on the glycoproteins as a result of modification 
in the Golgi assign more specific and novel functions (Helenius A et al, 2001). 
 
 
Terminal mannoses potentially recognized by LMAN1 
joined by α (1-2) linkage 
Figure 13. Biosynthesis of N-linked core glycans and recognition of potential cargo by 
LMAN1 (Pattison R & Amtmann A, 2009) 
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In the biosynthesis of N-linked glycans, initially the process begins in the 
cytosolic surface of the ER membrane when a 14 saccharide “core” unit is put 
together, by the addition of one sugar at a time to dolichylphosphate. After two N-
acetylglucosamines and five mannoses are added to the precursor, the oligosaccharide 
flips to the lumenal side where seven more glucose units are added. Oligosaccharide 
enzyme complex transfers this core unit to the nascent polypeptide chain, after the last 
three glucoses are conjugated. Immediately after the transfer, the last three glucose 
units are trimmed off by glucosidase I and II, followed by further trimming of 
terminal mannoses by one or more different ER mannosidases. Glucosyltransferase, 
together with glucosidase II can reglucosylate glucose free chains and thus establish a 
deglucosylation-reglucosylation cycle. After the action of glucosidases, calnexin-
calreticulin cycle folds the protein. At this step, the newly synthesized protein is 
folded (Figure 13). 
Meanwhile LMAN1 monomers synthesized in the lumen of the ER are 
anchored to the ER membrane by their transmembrane domain (Figure 14) (Hauri H- 
P et al, 2000). These monomers are then oligomerized. Keeping in mind the 
localization of LMAN1 mostly in the ERGIC and also sometimes in ER, it is likely 
that LMAN1 captures its cargo- Man8-N-Glycans derived from Man9(GlcNAc)2 
(Figure 13) after the initial processing and trimming in the ER. LMAN1 recognizes 
and binds the terminal mannoses. However it should be noted that the exact ligand for 
LMAN1 is still ambiguous. It has been reported to bind to both Man9 as well as Man8 
structures (Appenzeller C et al, 1999) but in either case it seems logical that LMAN1 
would interact with the terminal mannoses joined by α (1-2) glycosidic bond of Man9 
or Man8 glycoproteins. After LMAN1 conjugates with its cargo glycoprotein, the 
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complex of cargo-LMAN1 is recruited to budding vesicles by interaction of FF 
residues in the cytoplasmic domain of LMAN1 with COPII coat (Figure 14).  
As a result, vesicular transport to the ERGIC takes place. In the ERGIC, the 
cargo is released and LMAN1 is recycled back to ER via interaction of KK residues 
and COPI coat in a retrograde transport. The folded protein is then directed for 
anterograde transport to the Golgi complex (Hauri H-P et al, 2000).  
 
 
 
1.3.4 Other potential cargo receptors in mammals 
Apparently there are no other definitive cargo receptors known in mammals 
except the LMAN1- MCFD2 complex. But research revealed the presence of some 
other receptors in yeasts and it is likely that their homologs might serve as cargo 
receptors in higher eukaryotes. One such example is the p24 protein family but the 
function of the mammalian homolog varies from that of the yeast. One member of this 
Figure 14. Cargo receptor function and recycling of LMAN1 (Hauri H-P et al, 2000) 
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family, p21 is a transmembrane trafficking protein of amyloid precursor protein and 
regulates secretase activity (Orci L et al, 2003).  
LMAN1 is a member of animal L-type lectin family of protein, the other 
members of this family includes LMAN1-like protein(LMAN1L), LMAN2(also 
called VIP36) and LMAN2 like protein(LMAN2L or VIPL) (Nufer et al, 
2003). LMAN2 and LMAN2L are promising cargo receptors based on some early 
evidences (Neve et al, 2003). BAP31 or the B cell receptor associated protein is 
another of the potential cargo receptors which might be involved in selective transport 
of MHC-I molecules (Zhang Y & Williams D, 2006).  
1.4. Multiple coagulation factor deficiency 2 (MCFD2): Partner of LMAN1 in 
cargo capture & trafficking 
MCFD2 is a small 16-kDa protein, soluble in nature having an N terminal 
sequence containing 42 amino acids and 2 calmodulin like EF hand domains at its C 
terminus. The EF hand domain contains a Ca2+ binding loop flanked by 2 α helices. In 
MCFD2 there are total 4 α helices and they are designated as helix 1 through 4. The 
EF hand domains of MCFD2 are connected by a linker region which is largely 
unstructured and of 10 amino acids long (Guy J et al, 2008).  
MCFD2 homologs exist in different species of eukaryotes like rat, cow and 
fish. NMR studies have revealed that Ca2+ induces proper folding of the EF hands of 
MCFD2. In absence of Ca2+ the protein became disordered and the characteristics 
resembled that of an unfolded protein. Secondary structure or the existence of a 
hydrophobic core of the protein could not be determined in absence of calcium. 
However, in presence of the metal ion, both secondary and tertiary structures existed 
(Figure 15) (Guy J et al, 2008). 
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LMAN1 forms a Ca2+ dependent complex with MCFD2 in a 1:1 stoichiometry. The 
β1 strand of the CRD of LMAN1 binds to the EF hand domain of MCFD2 and the 
LMAN1-MCFD2 complex interacts with cargo proteins FV and FVIII. Interaction of 
the cargo molecules with this complex is independent of the glycosylation state of the 
coagulation factors but is necessitated by calcium concentration in the ER (Zhang B et 
al, 2005). Unlike LMAN1, MCFD2 lacks the ER exit and retrieval motifs and the 
localization of MCFD2 in the ERGIC is dependent on LMAN1. LMAN1 has several 
other potential cargos in addition to FV and FVIII, but the role of MCFD2 in 
trafficking of these cargo proteins is not clear. MCFD2 missense mutants identified in 
F5F8D patients failed to form complex with LMAN1, however it was still able to 
interact with FVIII (Zhang B et al, 2005). This suggested that interaction of MCFD2 
with the blood coagulation factors was independent of its interaction with LMAN1 
(Zhang B et al, 2005). As mentioned earlier 30% of the F5F8D patients have 
mutations in MCFD2, from this it is definite that this protein also play a pivotal role 
in the cargo capture but the molecular mechanism and in depth function of this protein 
is still unknown.  
Mutagenesis studies and circular dichroism spectroscopy revealed that the EF 
hand domains of MCFD2 are sufficient and necessary for interaction with LMAN1 
(Zheng C et al, 2010a). Crystal structure of the CRD-MCFD2 complex confirmed the 
interaction of the EF hand domains of MCFD2 with the N-terminus of LMAN1 
(Nishio M et al, 2010, Wigren E et al, 2010). EF hand domains of MCFD2 also 
mediate its interaction with FV and FVIII, but the sites of interactions are different 
from those involved in LMAN1 binding. From the more profound decrease in FV and 
FVIII levels observed in F5F8D patients with MCFD2 mutations (Figure 2), it seemed 
like MCFD2 plays a more direct role in cargo receptor function. It is likely that 
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MCFD2 recruits the cargo and brings FV/FVIII in close proximity of LMAN1 for 
further interactions.  
  
 
 
Figure 15. (A) MCFD2 domain structure. (B) NMR structure of MCFD2- left: complete 
structure, right : EF hand domain. (C) Stereo view showing the mutations in ordered 
EF hand domain (shown in color) of MCFD2. The cyan spheres represent Calcium ions 
(Guy J et al, 2008) 
Ordered EF 
hand domain 
of MCFD2 
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CHAPTER II 
MATERIALS AND METHODS 
2.1 Plasmid construction 
To understand the mechanism of cargo release by LMAN1, we need to purify 
its functional carbohydrate recognition domain (CRD) which is the part of the 
molecule that binds to its cargo. For this purpose we designed our construct to express 
the CRD in E. coli.  
2.1.1 Designing the fusion protein 
Initially we created a fusion protein where our target protein (CRD) was fused 
with GST to enhance its solubility and facilitate in the purification process by affinity 
chromatography. For designing the fusion construct, we used pSJ6 plasmid that is 
derived from pET41a (Novagen) strain of E.coli and contains a GST tag, His8 tag and 
a TEV protease cleavage upstream of BamH1 restriction site. The GST coding 
sequence was amplified from pSJ6 plasmid using forward primer 
tataccatgggatcccctatactaggttattgg and reverse primer tataccatggcatccgattttggaggatgg 
which incorporated Nco1 site at the start and end position.  
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Amplified GST was digested with Nco1(New England BioLabs) and was 
ligated to Nco1 digested pET15b vector into which residues 31-263 corresponding to 
the CRD of human LMAN1 was cloned between BamH1 and Nde1 sites. The amino 
acid sequence of the CRD that was cloned for our research is: 
dgvggdpava lphrrfeyky sfkgphlvqs dgtvpfwaha gnaipssdqi rvapslksqr gsvwtktkaa 
fenwevevtf rvtgrgriga dglaiwyaen qglegpvfgs adlwngvgif fdsfdndgkk nnpaiviign 
ngqihydhqn dgasqalasc qrdfrnkpyp vrakityyqn tltvminngf tpdkndyefc akvenmiipa 
qghfgisaat ggladdhdvl sfltfq 
Nco1 digested plasmids were ligated such that GST is in the N terminal of the 
CRD with quick ligase enzyme (Promega) and the ligated plasmid was transformed 
into DH5α cells (Invitrogen) followed by extraction of the plasmid (pET15b-GST-
CRD) from the inoculated culture using Qiagen Miniprep kit. The extracted plasmid 
samples were confirmed by sequencing analysis before using them for transformation 
into BL21 cells to produce the fusion protein. Colonies from BL21 cells were 
inoculated in overnight express instant TB medium (Novagen) at 16°C for 60 hours. 
Auto induction media at lower temperature for a longer period of time enhances the 
solubility of the target protein. The cells were then harvested and lysed by sonication 
(with 550 Sonic Dismembrator from Fisher Scientific, total sonication time 15 
minutes, with 15 seconds  “on” and 15 seconds “off” pulses) using 50 mM Tris-HCl, 
250 mM NaCl, and 20 mM CaCl2, adjusted to pH 8.0. The lysed cell suspension was 
centrifuged at 20,000g for 20 minutes at 4°C.  
The supernatant was purified using GSTrap 4B 1ml column from GE Life 
Sciences using the same buffer as mentioned earlier for binding and washing. The 
flow rate for the entire purification process was optimized to 0.5 ml/min for maximum 
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binding. After washing the column with 30 column volume (CV) of wash buffer (to 
remove nonspecific proteins), the recombinant protein bound to the column was 
eluted using 50 mM Tris-HCl, 250 mM NaCl, 20 mM CaCl2, 50 mM L-Arginine and 
20 mM reduced Glutathione (GSH), adjusted to pH 8.0. 
The eluted sample was then subjected to overnight digestion at 4°C by 
Thrombin (5 U/mg from Sigma) to cleave the GST tag. Simultaneously the sample 
was also dialyzed overnight to remove GSH. The dialyzed and digested sample was 
then re-purified using the same GSTrap column and the buffer that was initially used 
for binding and washing. The purified target protein was collected in the flow-through 
fraction. At each step of purification, all fractions were collected to be analysed by 
electrophoresis to determine the correct molecular weight and the purity of the target 
protein sample. 12% Precast Tris-Hepes gel (Thermo Scientific) was used for 
electrophoresis of the samples using Hepes buffer and SeeBluePlus2 Prestained 
Protein Standard 1X (Invitrogen). 
2.1.2 Designing the construct pET15b-CRD (wild type)  
2.1.2.1 Making the insert  
The CRD of human LMAN1 corresponding to amino acids 31-266 was 
amplified by forward primer LMAN1-CRD-S: GAGTC TCATAT Ggacg gcgt gggag 
gagac that introduced Nde1 site at the beginning and reverse primer CRD-AS-L: 
GACTG GATCC tcaag gttca gtcaa ctggaaag incorporating a BamH1 site at the end. 
This differed from the other construct that we used for creating fusion protein by 
having 3 extra amino acids – T, E and P at the C terminal end. Hence this new CRD 
had sequence: dgvggdpava lphrrfeyky sfkgphlvqs dgtvpfwaha gnaipssdqi rvapslksqr 
gsvwtktkaa fenwevevtf rvtgrgriga dglaiwyaen qglegpvfgs adlwngvgif fdsfdndgkk 
33 
 
nnpaiviign ngqihydhqn dgasqalasc qrdfrnkpyp vrakityyqn tltvminngf tpdkndyefc 
akvenmiipa qghfgisaat ggladdhdvl sfltfqtep 
F-549 S Phusion Hot Start High- Fidelity DNA Polymerase (2U/µl) along with 
F-518 5X Phusion HF buffer containing 7.5 mM MgCl2 from Finnzymes now known 
as Thermo Scientific is used for amplification. 
We set up 100 microliter reaction for the amplification of the CRD of 
LMAN1. Techne TC 512 served as thermal cycler for this purpose. 
The pipetting protocol for setting up the PCR is: 
Component 100µl Reaction  Final Concentration  
H2O 66 µl  
5X Phusion HF buffer  20 µl 1X 
10 mM dNTPs 2 µl 200 µM each 
10µM Forward Primer 5 µl 0.5 µM  
10µM Reverse Primer 5 µl 0.5 µM 
Template DNA 1 µl 40 ng 
Phusion Hot Start II DNA 
Polymerase  
1 µl 0.02 U/µl 
 
We followed a 3 step cycling process for the amplification. The CRD of LMAN1 is 
720 base pairs; hence accordingly the annealing temperature and extension 
temperature was calculated. The amplification process was:
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Cycle Step Temperature Time Cycles 
Initial Denaturation  98°C 30 s 1 
Denaturation 
Annealing 
Extension 
98°C 
59°C  
72°C 
15 s 
30 s 
25 s 
 
25-35 
Final extension 72°C 10 min 1 
 
Since our amplified PCR product- the longer form of CRD was in the 
specified range of 10-100kB of QIA quick PCR Purification Kit, it was purified using 
this kit to remove primers, nucleotides, polymerases and salts. The DNA was finally 
eluted from the QIAquick column using 50µl of double distilled H2O. Concentration 
and quality of the eluted plasmid is estimated by Nanodrop ND-1000 
spectrophotometer and is found to be 97.1 ng/µl. 
50 µl of the eluted plasmid was set up for digestion with Nde1 (New England 
BioLabs, strength 20,000 u/ml) and BamH1 (New England BioLabs, strength 20,000 
u/ml) with NE Buffer 3 (New England BioLabs, 10X concentration) and purified 
BSA (New England BioLabs, 100X) at 37° C for three and half hours. 
Component Amount 
Amplified CRD long form 34 µl 
H2O 7.5 µl 
Bam H1 1.5 µl 
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NdE1 1.5 µl 
NE buffer 3 5 µl 
BSA 0.5 µl 
 
The digested product was again purified using the QIAquick PCR purification 
kit. Concentration of the digested product was estimated by Nanodrop 
spectrophotometer and concentration was 60 ng/µl. This would serve as the insert for 
the vector used for expressing the CRD of LMAN1. 
2.1.2.2 Choosing the vector  
For cloning the insert, we decided to use pET15b vector from Novagen (Cat. 
No. 69661-3). This carried an N terminal His tag sequence followed by a thrombin 
site and three restriction sites.  
We already had the construct where the regular CRD (without three extra 
amino acids) was ligated into pET15b vector. This vector was digested (described in 
the previous section) with Nde1 and BamH1 which removed the regular CRD from 
the vector. The concentration of the vector was 300 ng/µl and a 50 µl reaction was set 
up as described earlier. After digesting the vector for three hours at 37°C water bath, 
the sample was electrophoresed on a 0.8% agarose gel. The double enzyme digestion 
with BamH1 and Nde1 resulted in 2 bands on the agarose gel – a shorter band which 
is the CRD 720 bp and a bigger band of the vector running at ~ 5.7 kB (comparing 
with 1 kB plus ladder from Invitrogen). The empty vector was then gel extracted 
using QIAquick Gel Extraction Kit and concentration is again estimated with 
Nanodrop spectrophotometer. It was 12.5 ng/µl.  
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2.1.2.3 Ligation  
The digested insert and the empty vector was ligated using T4 DNA Ligase (3 
u/µl from Promega) and 2X ligation buffer (Promega) incubating the samples at room 
temperature for 10 minutes. The volume of vector and insert used for ligation was in 
the ratio of 1:3. One control tube was set up with just vector and ligation mix but 
without the insert.3 µl of the ligation mix from each tube was then used for 
transforming 40 µl of DH5 α competent cell from Invitrogen. The transformed 
samples were incubated in ice for 30 minutes followed by heat shock at 42°C water 
bath for 25 seconds and 2 minutes incubation in ice. Finally, 500 µl of SOC medium 
(Sigma) was used to recover the cells and was then incubated in a 37°C shaker for one 
Figure 16. pET15 b vector sequence 
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hour. The transformed cell suspension (100 µl) was then spread on an ampicillin plate 
and kept in a 37°C incubator overnight. 
2.1.2.4 Cloning  
Several colonies of DH5α cell transformed with the CRD in pET15b vector 
were picked up from the ampicillin plate and inoculated in 3 mls of LB with 3µl of 
the ampicillin. This was allowed to grow overnight in 37°C shaker followed by 
plasmid extraction with QIAprep Miniprep Kit. These plasmids were then digested 
with Nde1 and BamH1 to screen for the right insert. The digested samples were 
electrophoresed on a 1.5% agarose gel to confirm the presence of the correct insert. 
Finally the desired colonies were sent for sequencing with primer 
TAATACGACTCACTATAGG. Of the six colonies, only one carried plasmid DNA 
with the correct insert and the vector. This is our wild type pET15bCRD construct. 
2.2 Constructing mutant plasmids with pED vector 
For preparing mutant LMAN1 in mammalian cells, we used a different vector 
called pED. Flag tagged full length LMAN1 was derived from pED-LMAN1 
(Moussalli M et al, 1999) by replacing the LMAN1 signal sequence with that of 
calreticulin and introducing a flag tag after the signal sequence. This was used as the 
template for generating mutant plasmids. Point mutations were introduced at S88A 
(forward primer: caa att cga gta gca cca tct tta aaa gcc caa aga ggc tcag  & reverse 
primer: ctg agc ctc ttt ggg ctt tta aag atg gtg cta ctc gaa tttg), H-178A (forward primer: 
atg gac aaa tcc att atg acg ctc aaa atg acg ggg cta gtc & reverse primer: gac tag ccc cgt 
cat ttt gag cgt cat aat gga ttt gtc cat), F154Y (sense primer: gga atg gtg ttg gaa tat ttt 
ttg att ctt atg aca atg atg gaa aga aaa ata & antisense primer: tat ttt tct ttc cat cat tgt cat 
aag aat caa aaa ata ttc caa cac cat tcc), G251A/252A (sense primer: gaa tat ctg ctg caa 
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ctg cag ctc ttg cag atg acc atga & antisense primer: tca tgg tca tct gca aga gct gca gtt 
GCA gca gat attc) using QuikChange II XLSite-Directed Mutagenesis Kit (Agilent 
technologies/Stratagene). All mutations were confirmed by sequencing with primer 
aacgc gactg caggt cgaca tgctg ctatc cgtgccgc.  
 
2.3 Protein expression and purification 
2.3.1 Expression host transformation using the construct pET15bCRD 
The construct pET15bCRD was used for transforming BL21 cells from 
Invitrogen which served as the host. BL21 was one of the several different host strains 
available as DE3 lysogens. Transformation procedure was same as described earlier. 
The only difference was now for transformation into an expression host, 1µl (~ 1ng) 
of plasmid in sterile water was used. The transformants were streaked on a plate for 
single colonies.  
2.3.2 Induction of lysogen  
After the target plasmid was established in BL21 cells, expression of the target 
DNA (pET15bCRD) was induced by the addition of IPTG to a growing culture. For 
full induction, we used a final concentration of 1 mM of IPTG.  
To prepare for induction, a single colony from a freshly streaked plate was 
inoculated into 4 mls of LB containing ampicillin. This was allowed to grow in a 
37°C shaker, 230 rpm until the OD600 reaches 0.6-1.0. 500 µl of this culture was then 
allowed to inoculate 500 mls of LB at 37°C shaker until the OD600 reaches 0.8-1.0. 1 
mM IPTG was then added and incubated for 4-5 hours more. A small volume of 
uninduced sample was set aside for control.  
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2.3.3 Confirmation by SDS-PAGE 
Bacterial pellets were harvested from small volumes (1ml each) of induced 
and uninduced samples on a table top centrifuge 5415 R (Eppendorf). The pellet was 
lysed by sonication using lysis buffer [50 mM Tris-HCl and 150 mM NaCl (pH 7.4)], 
supernatant was electrophoresed on a reducing gel to confirm the expression of the 
target protein, the CRD of LMAN1.  
2.3.4 Preparation of inclusion bodies  
Bacterial pellet was harvested from the remaining of the induced culture by 
centrifugation at 6,000g for 15 minutes in a Sorvall RC 6 centrifuge from Thermo 
Scientific. After washing the pellet with water once, it was resuspended in lysis buffer 
(50 mM Tris-HCl, 150 mM NaCl, pH 7.4). For complete resuspension the volume of 
lysis buffer used was optimized to 7 ml/gm wet weight of bacterial pellet. About 1 mg 
of lysozyme (Fisher Scientific BP535-1) per 10 ml was added to the resuspended 
culture and incubated in ice (4°C) for 30 minutes with occasional swirling. The 
bacterial cells were then lysed by sonication with 550 Sonic Dismembrator from 
Fisher Scientific at power 4 on a 10 seconds “on” and 10 seconds “off” cycle for a 
total duration of 15 minutes at 4°C. After cell disruption, cellular DNA is digested by 
adding 10 units of DNase I (1u/ml from 2500u/ml stock of DNase I) and 3 mM of 
MgCl2 were added and incubated at room temperature for 20 minutes. This 
combination of enzymatic and mechanical cell lysis would render in maximum cell 
disruption. Finally the inclusion bodies were harvested from the cell lysate by a 
Sorvall RC6 centrifuge at 26,000g for 30 minutes at 4°C. 
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2.3.5 Washing of inclusion bodies 
Once we had isolated the inclusion bodies with the target protein, we needed 
to wash it in order to reduce contaminant levels. We used two different types of wash 
buffer for this process and referred it as Wash Buffer 1(1.5 M NaCl, Triton X-100 
2%, 20 mM EDTA, pH 7.0) & Wash buffer 2(0.1 M Tris-HCl, 20 mM EDTA). The 
inclusion bodies were completely suspended in 30 mls of Wash buffer 1 and collected 
by centrifugation at 6,000 g for 15 minutes at 4°C. This step was repeated twice for 
each of the buffers. This stringent method of washing would yield 80% pure inclusion 
bodies.  
2.3.6 Protein refolding 
 In order to obtain functional target protein, we needed to solubilize the 
inclusion bodies in detergents or surfactants to release the protein followed by 
refolding of the solubilized protein to give them native three dimensional 
conformations. There were different methods for solubilization and refolding that can 
be followed. In the following page, there is a schematic representation of the various 
solubilization and refolding strategies (Figure 17).  
A. Solubilization: For our purpose, we suspended inclusion bodies in 6 M GuHCl 
such that the protein concentration is 5-8 mg/ml and incubated at room temperature 
for 30 minutes. The concentration of solubilized protein was determined by Bio-Rad 
Protein Assay based on the principle developed by Bradford. We used microtiter 
plates and recorded the absorbance on an absorbance microplate reader (Spectraplus 
Max 384 from Molecular Devices) set at 595 nm. The standard curve was prepared 
using serial dilutions of BSA from 2 mg/ml to 10 mg/ml. The supernatant was 
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collected after centrifuging the samples on a table top ultracentrifuge (5415 R from 
Eppendorf). 
 
 
 
B. Renaturation of released protein: Refolding was carried out in a redox 
environment using oxidized and reduced glutathione. After several tries, the refolding 
buffer that worked best for our protein was composed of 50 mM Tris-HCl, 0.4 M L- 
arginine, 5 mM reduced glutathione and 0.5 mM oxidized glutathione (pH – 8.0). The 
volume of refolding buffer was optimized such that finally the solubilized protein 
would be diluted 150 folds (~120 µg/ml). Solubilized sample was added to refolding 
buffer in pulses (1 ml per injection) over a period of 36 hours and the entire protocol 
was carried out in 4°C. Since we were dealing with large volumes of buffer, the 
refolded protein sample needed to be concentrated by Amicon Ultra 15 Centrifugal 
Filter Units with 10 kDa cut off from Millipore. Final volume of the refolded protein 
was reduced to 1ml at concentration of ~ 8-10 mg/ml. 
Additives that may enhance refolding – e.g. Oxidized/reduced Glutathione, 
Cysteine/Cystine, Oxidized/reduced Dithiothreitol 
Figure 17. Schematic Representation of various solubilization and refolding strategies 
(Represented from Novagen Protein Refolding Kit manual) 
42 
 
2.3.7 Protein purification 
We used gel filtration chromatography (size exclusion chromatography) as the 
preferred method for our experiment to remove the nonspecific contaminants. Our 
target protein, the purified CRD monomer has a MW of 28.6 KDa; hence Superdex 75 
column was chosen for purification purpose as it is efficient for separating proteins in 
the range of 3-70 KDa. We passed our refolded and concentrated sample through 
Superdex 75 column (10/300Gl, Code No. 17-5174-01) in Hepes buffer (10 mM 
Hepes, 150 mM NaCl, pH 7.4) using the AKTA purifier UPC900 (GE healthcare).  
The entire purification process was carried out at 4°C. The column volume 
was 24 mls and initially it was equilibrated with 2 column volume (CV) each of 
ddH2O and the Hepes buffer. After the equilibration, the purification process was 
started through the software (Unicorn) controlling the purifier. In each injection, 500 
µl of the concentrated sample was loaded in the purifier using a (Hamilton) syringe of 
similar volume. All the peaks recorded in the chromatogram were collected for 
analysis by SDS-PAGE. After the purification process was over, we used the same 
column for separating protein standard (Gel Filtration Standard from Bio-Rad).  
All samples were electrophoresed on a NuPAGE 4-12% Bis-Tris gel 
(Invitrogen) using MES buffer (50 mM MES, 50 mM Tris –base, 3.5 mM SDS, 0.8 
mM EDTA) and SeeBluePlus2 Prestained Protein Standard 1X (Invitrogen). The gel 
was stained with Coomassie blue G-250 for 1 hour and destained with ddH2O for 3-4 
hours. The SDS-PAGE results confirmed that the peak 2 from the purification is 
definitely our desired protein CRD monomer.  
The purified sample corresponding to peak 2 had a volume of ~ 5 mls which 
was further concentrated using Millipore Amicon Ultra 10K 4 mls tube. Quantity of 
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the protein in the concentrated sample was estimated by Bio-Rad Protein Assay. It 
was observed that the yield of purified CRD is ~ 50% compared to the concentration 
of the solubilized inclusion bodies. Hence the steps of protein expression through 
purification were done in batches, repeating it several times to get enough amount of 
protein for further biochemical experiments.  
2.4 Expression and purification of MCFD2  
MCFD2 was ligated to pET15b vector in a similar way as described in Section 
2.1. Likewise it was cloned in DH5α cells (procedure same as section 2.1.6). 
Eventually the construct was expressed in BL21 cells and the soluble fraction of the 
cell lysate was harvested (procedure same as in section 2.2).  
For purification of MCFD2 we used a modified approach of the 
QIAexpressionist kit which is based on the principle of immobilized metal affinity 
chromatography (IMAC) as our construct has 6x histidine tagged on the N terminal 
end. Bacterial pellet from 250 ml culture was obtained by centrifugation at 6,000 g for 
20 minutes. The pellet was then resuspended in 2 ml/gm wet weight of lysis buffer 
(50 mM Tris-HCl, 50 mM NaCl and 10 mM imidazole adjusted to pH 7.5). The 
resuspended pellet was incubated at 4°C for 30 minutes with ~1 mg of lysozyme and 
1 protease inhibitor cocktail tablet (Roche Diagnostics) followed by lysing the cells 
with a sonicator (550 sonic Dismembrator from Fisher Scientific ) set to power “4” in 
a 10 seconds “on” and “off” cycle for a total duration of 8 minutes. The crude cell 
lysate was treated with 10 units of DNase per 10 mls and 3 mM MgCl2 and incubated 
at 4°C for 15 minutes. MCFD2 being a soluble protein, the supernatant was collected 
after centrifugation (Sorvall RC 6 centrifuge) at 26,000 g for 30 minutes at 4°C.From 
500 ml of bacterial culture, the volume of clear cell lysate obtained was ~10 ml. 
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Meanwhile 1 ml of the 50% Ni-NTA slurry was added to a 15 ml falcon tube, 
centrifuged at 1,000 rpm for 2 minutes and the supernatant is decanted. The slurry 
was then completely resuspended in 4 ml of lysis buffer for equilibration and then the 
buffer is decanted by centrifuging for 2 minutes at 1,000 rpm. Clear cell lysate was 
added to the equilibrated slurry and mixed gently by shaking (~200 rpm) at 4°C for 60 
minutes. The lysate-Ni NTA was then loaded in a column and flow-through collected 
for SDS PAGE analysis. This was followed by washing the lysate-Ni NTA mix  with 
4 ml of wash buffer 2 (50 mM Tris-HCl, 50 mM NaCl, 20 mM imidazole, pH 7.5) and 
wash fraction was collected in separate tubes for every 1 ml for SDS-PAGE analysis. 
Finally MCFD2 is eluted 4 times with 1 ml elution buffer (50 mM Tris-HCl, 50 mM 
NaCl and 250 mM imidazole adjusted to pH 7.5). Each elution fraction is collected in 
separate tubes.  
SDS-PAGE analysis on a 4-12% gel (NuPAGE 4-12% Bis-Tris gel from 
Invitrogen) with MES buffer revealed that the 1st and 2nd elution fractions contain our 
protein of interest. The first and second elution fractions were then combined and the 
volume was reduced to 1ml by Amicon Ultra Centrifugal Filter Units with 3 KDa cut 
off.  The concentrated sample was digested with thrombin overnight (5u/mg of 
protein) to remove the histidine tags and then purified with superdex 75 column. 
Functionality test was then carried out with the purified protein by ITC assay as 
described in Section C. MCFD2 is similar to the CRD with 2 Ca2+ binding sites.  
2.5 Isothermal titration calorimetry (ITC) 
For this assay, we used a single injection instrument ITC200 from Microcal. 
Initially a control experiment was done by injecting 200 µl of the same Hepes buffer 
used for gel filtration chromatography in the sample cell but without the 
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macromolecule (the purified CRD monomer) as well as to the reference cell and is 
titrated against 5 mM Ca2+ dissolved in same buffer. The control experiment was 
followed by injecting 200 µl of the purified CRD monomer (200 µM) in the sample 
cell; the reference cell contains only the buffer minus the macromolecule and titrated 
with 5 mM Ca2+. The ligand concentration should be ideally 10-100 folds higher than 
the macromolecule. The parameters of the titration were entered into the software 
program controlling data acquisition. The number, volume, and length of time of 
injection are critical. The total number of injections was set to 20 and each time 2 µl 
of the ligand was injected into the sample cell. The experiment was carried out at 
room temperature (25°C). The space between each injection was about 3 minutes. 
Each peak displayed in the monitor represented a heat change and this heat change 
was plotted for each injection to get the binding curve. The binding curve was then 
analysed with the appropriate binding model to determine by binding constant, 
stoichiometry and entropy.  
ITC assay was also used for determining the binding constant of the CRD with 
its ligand mannobiose 2α (Sigma) where the functional CRD (200 µM) in 10 mM 
Hepes, 150 mM NaCl and 5 mM Ca2+,pH 7.4 served as the titrant and the titre is 30 
mM of mannobiose 2α. To check the effect of pH on the refolded and functional 
CRD, 200 µM CRD was titrated with 2 mM Ca2+ but at different pH of the buffer. 
Three buffer conditions were used – 10 mM Hepes, 150 mM NaCl at pH 6, 6.5 and 
7.4. We also titrated the purified CRD with 30mM mannobiose 2α at different Ca2+ 
concentrations (2 mM and 0.4 mM).  
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2.6 Crystallization of CRD monomer with mannose α (1-2) Mannose 
[commercially 2α mannobiose] 
Our purified CRD monomer was in 10 mM Hepes, 150 mM NaCl at pH 7.4. 
For crystallization, the CRD was required to be in a buffer with 10 mM Hepes, 50 
mM NaCl, and 4 mM CaCl2 at pH 7.4. So a crystallization buffer was prepared with 
10 mM Hepes and 6 mM CaCl2, adjusted to pH 7.4.  Now 2 parts by volume of this 
crystallization buffer was mixed with 1 part by volume of the purified CRD monomer. 
This was then concentrated to 10 mg/ml and divided into two tubes. To one tube, 100 
mM D (+)-mannose (Sigma) was added and to other tube 10 mM of mannobiose 2α 
(Sigma) is added. These samples were used for crystallization of CRD with its ligand.  
2.7 Cell culture and transfection of COS1 cells 
Vials containing COS1 cells from liquid nitrogen were quickly thawed at 37°C 
water bath with intermittent shaking. The contents of the vial were then pipetted 
gently into a 15ml falcon tube containing 5 ml Dulbecco’s Modified Eagle medium 
supplemented with 10% fetal bovine serum and penicillin-streptomycin. The contents 
were then spun at 1,000 rpm for 5 minutes and the supernatant discarded. The cell 
pellet was washed once more with the 10 ml of media. Finally the cells were seeded 
on a 10 cm plate with ~8 mls of media that was warmed at 37°C water bath.  
After 24 hours the growth media for cells were changed and after 48 hours, 
cells were given their first passage. When the cells were about 100% confluent and 
healthy, they were split again in a 1:4 ratio into five 100 mm plates. The following 
day COS1 cells were about 80% confluent and ready for transfection.  
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Five different plasmids were used for transfection – wild type pED flag tagged 
full length LMAN1 as a positive control and 4 mutants – S88A, H178A, F154Y, 
double mutant G251A/252A. We used 4 µg of plasmid for each plate and Fugene 6 
(Promega) served as the transfection reagent. After the media of the five culture plates 
(when ready for transfection) were replenished with 7 ml of fresh media and kept 
back in the incubator; 2 ml of serum free media (for each 1 µg of plasmid, 100 µl of 
serum media is required) was taken in a tube. 60 µl of Fugene 6 (for every µg of 
plasmid, 3 µl of transfection reagent used, in total we had 20 µg of plasmid) was 
added to the tube containing serum free media. The mix was allowed to sit at room 
temperature for 5 minutes and then 412 µl of aliquot added to five tubes labelled with 
the corresponding mutants. 4 µg of each plasmid added to each tube and incubated at 
room temperature for 20 minutes. The contents of each tube were added to different 
culture plates drop wise and the plates were placed back in the incubator.  
2.8 Mannose binding assay  
Mannose binding assay was performed essentially as described in Zheng C et 
al, 2010b after making some modifications. Forty eight hours after transfection of 
COS1 cell with pED Flag LMAN1: wild type and the mutants, the cell culture plates 
were brought back and the media were removed. The plates were washed with ice 
cold 1X PBS and then 1 ml of homogenizing buffer (10 mM Tris [tris(hydroxyl 
methyl aminomethane)]-HCL, pH 7.4, 150 mM NaCl, 1 mM CaCl2,  and 1 mM 
MgCl2) with one protease inhibitor cocktail tablet was added to each plate. The cells 
from each plate were scraped off and lifted to separate tubes. The cells were 
homogenized with a ball bearing homogenizer at 18-µm clearance 20 times. To check 
whether the cells were properly disrupted or not, 20 µl of cell homogenate is mixed 
with Trypan blue in a 1:1 ratio and observed under microscope on a hemocytometer. 
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The remainder of the cell lysate was cleared by centrifugation at 600g for 10 minutes. 
Each step was carried on ice. The supernatant from each tube was then transferred to 
Beckman-Coulter 4.7 ml optiseal polyallomer centrifuge tubes and centrifuged at 
100,000 g for 1 hour at 4°C (Beckman Coulter Ultracentrifuge). The pellet was 
solubilized in the lysis buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM 
CaCl2, 1 mM MgCl2, and 1% Triton X-100 with protease inhibitor) on ice for 1 hour. 
This resuspended pellet was again centrifuged at 100,000 g for 1 hour at 4°C. The 
supernatant was dialyzed against binding buffer (10 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 10 mM CaCl2, 1 mM MgCl2 and 0.15% Triton X-100 ) overnight at 4°C 
followed by incubation of the dialysate with 40 µl of eqilibrated mannose beads (D 
mannose agarose, cross linked 4% beaded agarose from Sigma) overnight. The 
overnight incubated samples were centrifuged at 10.2 rcf at 4°C for one minute. The 
beads were washed three times with 1ml of binding buffer for every wash. The pellet 
was resuspended in 40µl loading dye (SDS and DTT), boiled at 95°C for 5 minutes 
and the supernatant was used for SDS-PAGE and Western blot.  
2.9 Western blot  
The samples were electrophoresed on a 4-12% NuPAGE Bis-Tris gel using MES 
(Sigma Aldrich) buffer [50 mM MES, 50 mM Tris –base, 3.5mM SDS, 0.8mM 
EDTA]. Small aliquots of samples prepared after dialysis was used as loading control 
as it was the start point of mannose bonding assay. Transfer was done using iBlot Dry 
Blotting system (Invitrogen) using 7 minutes for the transfer to a nitrocellulose 
membrane. After the preliminary blocking with 5% non-fat dry milk, overnight 
incubation of the membrane was done using mouse anti-Flag antibody (Sigma 
Aldrich) in 1:2000 dilution. After washing with PBS-T , it was followed by 1 hour 
incubation with secondary antibody (anti-mouse polyclonal conjugated with HRP 
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from Sigma Aldrich) in 1:10000 dilution, the membrane was washed with PBS-T 
three times, each wash being 10 minutes. Finally the expressed proteins were detected 
by treating the membrane for 5 minutes with a mixture of Lumigen PS-3 detection 
reagent Solution A (1 ml) and Solution B (25µl).  The membrane was then exposed to 
X-ray film at various lengths of time. 
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CHAPTER III 
RESULTS AND DISCUSSION 
3.1 Expression of the CRD of LMAN1 as a GST fusion protein and purification 
by GST column 
3.1.1. GST-CRD plasmid construction 
To elucidate the exact ligand binding site and study the interaction of the 
carbohydrate recognition domain (CRD) of LMAN1 with its cargo glycoproteins we 
decided to purify the CRD of LMAN1 before proceeding with the necessary 
biochemical experiments. The CRD of LMAN1 is mainly expressed in inclusion 
bodies even under conditions optimized for enhanced solubility. We reasoned that 
tagging with GST at the amino terminus could enhance the solubility of the CRD. The 
GST tag would also facilitate the purification process by affinity chromatography 
using immobilized glutathione. The fusion plasmid construction is a two-step 
procedure (details in chapter 2.1) -  
i. Amplification of GST from pSJ6 vector using Pfu 
                    The GST open reading frame was amplified from pSJ6 plasmid which 
was a modified form of pET41a vector (figure 18) (details in section 2.1).          
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ii. Ligating amplified GST with vector containing wild type CRD 
After we amplified GST with the high fidelity enzyme Pfu, it was ligated in 
frame to pET15b vector containing the wild type CRD of LMAN1 to generate GST-
CRD, a fusion gene encoding the fusion protein (details in Chapter 2.1).                                                       
 
 
 
 
Ligated colonies 
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Figure 18. Amplified GST is about 700bp. 
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Figure 19. Ligation of amplified GST into pET15b vector with CRD and digestion with Nco1. 
Sample 5 and 6 showed ligated colonies following NCo1 digestion. Band of GST is visible 
around 700bp. The four ligated colonies  were sequenced to confirm the fusion of GST to the 
CRD. Only Sample 1 had the correct insert and the vector. 
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3.1.2. Purification of the fusion protein 
The majority of the GST fusion protein accumulated in the cytoplasmic 
fraction was captured by the affinity medium and impurities removed by washing. 
The wild type fusion protein expressed from pET15b-GST-CRD was purified as 
mentioned in Chapter 2.1. The four most critical factors that were optimized during 
the protocol: 
a. The composition and pH of the binding and elution buffer 
b. The flow rate of the sample during purification that allows optimum binding to the 
column. 
c. The temperature at which the experiment was carried out. 
d. Ideal way to cleave the GST tag from CRD after purification 
           
 
 
After digestion 2
nd GST purification 1st GST purification 
17 
Figure 20. Coomassie Staining of SDS-PAGE of wild type GST-CRD fusion 
protein purified by GST column. The band of purified protein CRD is indicated 
by the red square. Signal strength of purified CRD is weak. 
28 
38 
49 
14 
KDa 
53 
 
After the first round of purification of the fusion protein by the GST column, 
apparently we observed no significant precipitation when the eluted sample was 
stored overnight at 4°C. To be sure of any protein loss due to precipitation, we 
centrifuged the sample before proceeding with thrombin digestion. A small volume of 
the supernatant was used for SDS-PAGE analysis while the rest of sample was 
digested with thrombin off-column overnight at 4°C. As observed in lane 7 of Figure 
20, the protein loss was minimal as indicated by the strong signal of the fusion protein 
around 50 KDa. Overnight digestion with thrombin resulted in large amount of 
precipitation and we electrophoresed both the supernatant and the pellet after 
centrifugation (lanes 8 & 9 of figure 20). When the digested sample (supernatant) was 
purified for the second time by GST column, our target protein (the purified CRD) 
was collected in the flow-through fraction and elution fraction yielded just the GST. 
The signal for the elution fraction was very strong after second round of purification 
as observed in lane-11 of figure 20. However, when the flow through fraction was 
analyzed, we observed a very weak band in lane-12 around 28.6 KDa. While carrying 
out the purification process we observed that considerable amount of protein was 
precipitating at each step of the protocol despite the efforts for optimization. From this 
we concluded that though we were successful in purifying the soluble CRD of 
LMAN1 but the yield was too low to carry out further biochemical experiments.  
This poor yield was possibly due to aggregation of the CRD after thrombin 
treatment. As was mentioned earlier, the CRD alone is mainly expressed in inclusion 
bodies. Even though GST tag improved solubility of the fusion protein, cleavage of 
GST tag by overnight treatment with thrombin resulted in aggregation of the CRD. 
Removal of GST is likely making the protein unstable causing some conformational 
changes. Hence the majority of the initially soluble CRD becomes insoluble after 
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digesting with thrombin. This can be the reason why we observed significant amount 
of precipitate post digestion.  
 
3.2 The CRD of LMAN1 expression and purification by the denaturation & 
refolding approach 
Since we were unable to get sufficient amount of the soluble CRD using the 
GST fusion protein, we attempted a new approach. Our target protein CRD normally 
was expressed in the insoluble fraction as inclusion bodies in denatured form, so we 
decided to refold it and give it a native functional three dimensional conformation. 
For this approach, we decided to modify a method that has been reported in a 
literature (Nishio M et al, 2010). The CRD of LMAN1 that was used for this purpose 
is slightly different from the one used for creating the fusion protein. This new 
construct had residues 31-266 corresponding to the CRD of human LMAN1 cloned 
into pET15b vector. Hence this was longer than the previously used CRD by 3 amino 
acids – T, E and P at the C terminal end which may contribute to increase the stability 
of the protein. This DNA fragment cloned into empty pET15b plasmid was confirmed 
by sequencing and found to be in frame, then it was expressed into BL21 cells (figure 
21) [details in Chapter 2.1].  
A control experiment was performed with the wild type protein to make sure 
that the protein was expressed and of right molecular weight (figure 22). Bacterial 
culture was lysed by sonication and total, soluble and insoluble fractions were 
electrophoresed on a 4-12% Bis-Tris gel using MES buffer and stained with 
Coomassie. 
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Amplification of CRD and ligation into empty pET15b  
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Figure 21. A. CRD of LMAN1 amplified by Phusion Hot Start DNA Polymerase and 
electrophoresed on a 2 % agarose gel with 1kb plus DNA Ladder. B. Amplified CRD is 
ligated into pET15B Vector and digested with Nde1 and BamH1, electrophoresed on 2% 
gel agarose gel to confirm the presence of insert.  The CRD alone (encircled by red ellipse) 
in 720 base pairs and vector is ~6.5kB (encircled by red square). Amplified CRD alone is 
also digested with enzymes and used as control (right lane beside 1kb plus ladder). 
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Figure 22. Coomassie R 250 staining of 
SDS-PAGE of the total, soluble and 
insoluble fractions of pET15BCRD 
expressed in BL21. The insoluble fraction 
shows that the target protein (marked by 
the red ellipse) is expressed and of the 
right molecular weight 28.6 kD. 
98 
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3.2.1 Preparation of inclusion bodies and release of target protein pET15bCRD 
Inclusion bodies are dense aggregates of misfolded polypeptides localized 
intracellularly in bacterial cytoplasm or sometimes in the periplasmic space. 
Aggregating characteristic of a protein or the dysfunction of the cellular machinery 
which under normal conditions is responsible for proper folding of the polypeptide 
contributes to the formation of inclusion bodies. Sometimes the inherent nature of a 
protein determines if it would be expressed in the soluble form or accumulates as 
inclusion bodies. In order to retain the functional 3D configuration, these misfolded 
polypeptides must be released from the inclusion bodies and refolded (Middelberg 
A.P.J, 2002). 
There are different approaches for release and refolding of the target proteins 
from the inclusion bodies (details in Chapter 2). One of the most commonly used 
methods for refolding is by dialysis as it is less time consuming. Hence, we harvested 
the inclusion bodies from bacterial cell lysate (details in Section 2.2) and followed the 
Novagen protein refolding kit for solubilization and refolding of inclusion bodies. 
According to this kit, dialysis was the preferred method for refolding. The kit used 
CAPS buffer along with 0.3% N-lauroylsarcosine to achieve solubility of the 
inclusion bodies followed by dialysis with Tris buffer. The problem that we 
encountered was yield of the refolded protein was poor and it was observed that large 
amount of it grouped and precipitated during the refolding process. It seemed like 
dialysis was not efficient enough to reduce the detergent concentration from our target 
protein and thereby enhance refolding. We carried out turbidimetric assay which 
confirmed beyond permissible levels of detergent in the protein. Hence we observed 
large amount of aggregated protein contributing to lower yield.  
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The other popular method for refolding of protein is by dilution. One of the 
important factors that contribute to improving the yield of target protein from 
inclusion bodies is the purity. Presence of contaminants in inclusion bodies is likely to 
reduce the yield of the refolded protein. So we modified our approach and developed 
a new method for washing, solubilization of inclusion bodies and refolding of the 
target protein. We followed a stringent wash method to harvest pure inclusion bodies. 
Enzymatic digestion of DNA, repeated washing with detergent (Triton X-100) and 
chelating agent (EDTA) yielded acceptably clean inclusion bodies. For solubilization 
we preferred 6 M guanidine hydrochloride (GuHCl) over any other denaturants like 8 
M urea because GuHCl is stronger and is thereby able to disintegrate otherwise robust 
inclusion bodies. Moreover, urea has a tendency to decompose to cyanate easily 
(Clark E.D.B et al, 1999).  
The complexity of protein refolding lies in the fact that the exposed surface of 
the protein interacting with solvent should be hidden and other molecules of the 
protein should be able to interact with each other by formation of hydrogen bonds, 
salt bridges and van der Walls interactions (Pierce M et al, 1999). Successful in-vitro 
protein refolding is initiated by reduction of denaturant concentration. We followed 
the pulse renaturation or dilution method for protein refolding as this was more 
efficient in removal of the denaturant and thereby prevent loss of protein by aggregate 
formation. Addition of solubilized sample into large volume of the refolding buffer in 
pulses over a period of 36 hours at 4°C not only diluted the solubilized protein sample 
but also reduced the amount of denaturant/detergent used for solubilization. Hence the 
repetitive dilution of unfolded protein would minimise the tendency to form 
aggregates. Moreover, L-arginine in the refolding buffer acted as a suppressor of 
protein aggregation by enhancing solubility of partially structured folding 
58 
 
intermediates. Since the CRD of LMAN1 contains one disulfide bond, refolding in 
redox milieu facilitated associated disulfide bond formation. Hence oxido-shuffling 
system with reduced and oxidized glutathione (GSH/GSSG) was used for oxidative 
refolding of the CRD. We optimized the conditions and found that 150 folds dilution 
of the protein (120µg/ml) in refolding buffer gave the maximum yield. 
3.2.2. Purification of refolded protein 
  It was likely that the refolded protein was contaminated with several other 
nonspecific bacterial proteins in the inclusion bodies, hence it was extremely 
important to purify it before using it for biochemical studies. To do this we used a gel 
filtration column equilibrated with Hepes buffer. Since our biochemical studies were 
mostly based in and around physiological pH levels this buffer seemed ideal for our 
purpose, as several articles suggested that Hepes works better for a wider pH range 
(6.6-9) compared to Tris which is good for pH 7.0 and above. Superdex-75 column 
was chosen for this purpose as it is efficient in separating proteins in the range of 3 
KDa–70 KDa and the CRD has a molecular weight of 28.6 KDa. During protein 
refolding by pulse renaturation, as the protein was diluted 150 folds, it resulted in a 
large volume of refolding buffer. Hence for each batch of protein purification, the 
volume was reduced by concentrating it to 1 ml before loading the sample in a 
Superdex 75 column. The only downside in pulse dilution method was that it was 
time consuming and required a large supply of the concentration device. Details of the 
purification process are in Chapter 2.  
A chromatogram was generated for each batch of protein purification by the 
Superdex column showing UV absorbance by each protein present in the refolded 
sample which is a mixture of target protein as well as nonspecific proteins. Proteins 
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were separated based on their molecular weight, with the largest protein being the first 
to exit the column.  
 
 
 
 
In the chromatogram (figure23), there were 3 peaks. The x axis showed the 
volume of the buffer passing through the column and at what volume of the buffer, 
the proteins were exiting the column. The UV absorbance on the y axis increased with 
the increase in concentration of each protein. Each of the fractions corresponding to a 
peak was collected for analysis by SDS-PAGE which gave us an idea about the purity 
of the sample and also confirmed the correct molecular weight of the CRD. Before 
performing the SDS-PAGE, we carried out the size exclusion chromatography of 
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Figure 23. Chromatogram from Superdex 75 column used for purification of CRD of LMAN1. 
The refolded and concentrated protein sample is loaded on the Superdex 75 column and 
fractions’ corresponding to each peak was collected. 
P2 (Purified CRD monomer) 
P1 
P3 
60 
 
protein standard (figure24) which is a commercially available mixture of proteins of 
known molecular weight. This informed us about the retention volume of purified 
CRD monomer, so that for subsequent purifications we know which peak to collect.  
 
 
 
 
After comparing with the protein standard and SDS-PAGE of the collected 
fractions confirmed that peak 2 from the Superdex 75 column was indeed purified 
CRD monomer (figure25). Though SDS-PAGE results showed a considerably strong 
band of the CRD in Peak 1, the retention volume of the Peak 1 fraction as observed 
during chromatography was around 10 ml. Compared with the protein standard, peak 
1 likely contained larger protein of MW greater than 44 KDa. It is possible that peak 1 
consisted of mostly aggregates of CRD which denatured during reducing PAGE.    
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Figure 24.  Chromatogram of Protein Standard. Comparing the chromatogram of protein 
standard to that of CRD purification,  since M.W of CRD of LMAN1 is 28.6kD,  it  is likely 
to  eluted in between 44kD (3rd peak) and 17kD (4th peak). This is the reason we labeled Peak 
2 of Figure 22 as purified CRD monomer. 
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3.3 Analysis of the interaction of the CRD with Ca2+ and the ligand at different 
conditions by isothermal titration calorimetry (ITC) 
The ITC assay is an efficient tool for quantitative determination of the 
thermodynamic aspects of any biochemical reaction. Whenever two molecules 
interact, either it is an endothermic reaction or an exothermic reaction. ITC assay is 
able to detect the heat released or absorbed during a reaction which is recorded over a 
time frame. For any ITC experiment, three factors are extremely critical- the ligand 
concentration, the macromolecule concentration and the choice of buffer. We 
accurately determined the concentration of the ligand and the purified CRD and 
optimized the buffer conditions before each experiment. Different parameters can be 
measured in a single ITC experiment like the stoichiometry of binding (n), the binding 
Figure 25.  Coomassie Staining of SDS-PAGE (using MES buffer) of the 
sample fractions collected from gel filtration chromatography of  the CRD 
of LMAN1. 
Purified CRD 
28 
17 
14 
6 
38 
49 
KDa 
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constant or the association constant (Ka), entropy(  Hb), enthalpy (   Sb) (Pierce et al, 
1999). However, for our purpose we determined the stoichiometry of binding (n) and 
the binding constant (Ka) which provided us the information on the molar ratio of 
interaction between the biomolecules and the strength of interaction respectively. 
3.3.1 Titration of the purified CRD with Ca2+ by ITC assay 
It was necessary to carry out a functionality test on the purified sample of the 
CRD to verify its correct folding before continuing with other biochemical 
experiments or utilizing it for solving the crystal structure of CRD of LMAN1 bound 
to mannose.  It is known that the CRD of LMAN1 has 2 Ca2+ binding sites (Velloso L 
et al, 2003). If each batch of the purified samples of CRD monomer can bind to 2 
Ca2+ ions, then it can be said that the sample is properly folded and functional. We 
used the ITC assay for this purpose. To determine the efficiency of the refolding 
process we titrated the purified CRD of LMAN1 (200 µM) with 5 mM Ca2+ at a 
neutral pH of 7.4. In figure 26 (top panel), the peaks that we observed represent the 
heat change that took place when Ca2+ ion interacted with the CRD in the sample cell. 
During the initial phase of the experiment, the peaks were higher indicating that the 
heat liberated is more, it gradually diminished as more and more ligand (Ca2+) was 
injected into the sample cell containing the CRD and the system progressively 
reached saturation. The raw data was then analysed by the Origin Software that came 
with the ITC device and fitted into an appropriate binding model to get the binding 
curve (Figure 26, bottom panel). The ITC result indicated that the stoichiometry of 
binding between the CRD and Ca2+ is 2 with a negligible error. Thus it can be inferred 
that our refolding method yielded a protein that is functional and regained its native 
confirmation. Not only did the ITC assay confirmed the presence of two binding sites 
on CRD for Ca2+ (Velloso L et al, 2003) it also provided additional information on the 
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binding affinity between the CRD and Ca2+. Binding affinity (KB) is defined by the 
dissociation equilibrium constant (KD, unit is M) which is the inverse of association 
equilibrium constant (Ka, unit is M-1). For tight binding complexes, Ka is in the range 
of 109-1010M (Pierce M et al, 1999) and hence the corresponding KD (dissociation 
equilibrium constant) is small. The smaller the KD value, slower is the rate of 
dissociation between the interacting molecules and hence stronger is the binding 
affinity (KB). In figure 26, we see that the Ka is 2.17E4 M-1 and thereby in the order of 
104 M-1. Hence KB = 1/ Ka = 2.17E4 M or in the order of 104M indicating the intensity 
of binding is moderate. For each batch of purified protein we carried out the ITC 
assay as a quality control experiment before utilizing the sample for other biochemical 
procedures (figure 26). 
 
Figure 26. The ITC results from 
titrating the CRD (200 µM) of 
LMAN1 with 5 mM Ca2+. Top 
panel indicates the heat change 
during the reaction. This is an 
exothermic reaction as indicated 
by the peaks. The lower panel 
shows the binding curve obtained 
by plotting the peaks if heat 
change against the ratio of the 
ligand and the binding partner in 
the cell. The binding curve is 
analyzed by fitting into an 
appropriate binding model. 
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3.3.2 Titration of the purified CRD with 2α-Mannobiose by ITC assay 
It was important to know whether the purified CRD of LMAN1 was able to 
bind to its ligand. Since LMAN1 binds to its cargo through the interaction of the CRD 
and the glycan (mannose) moiety of the cargo glycoprotein, we studied CRD-
mannose interaction as a proxy for LMAN1-cargo interaction (figure 27). This was 
done by titrating the purified CRD (200µM) against 30 mM mannose-α(1-2)-mannose 
(a dimannose covalently linked by α(1-2) linkage). We observed it was an 
endothermic reaction. This experiment also provided us the information on how 
strongly the CRD binds to ligand (cargo) mannose-α (1-2)-mannose (commercial 
available as 2α-mannobiose).  
 
Figure 27. The ITC 
result from titrating the 
CRD of LMAN1 (in 5 
mM Ca2+) with 30 mM 
2α mannobiose. The 
lower panel shows the 
binding curve when the 
heat change is plotted 
against the ratio of 2α 
mannobiose. The Ka is 
obtained by analyzing 
the binding curve by 
fitting into an 
appropriate binding 
model. Ka = 93.1 M-1. 
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As explained earlier, we can say from the ITC assay of the CRD titration with 
mannose-α (1-2)-mannose (figure 27), the binding affinity (KB) between the CRD and 
its ligand dimannose is weak as the Ka is only 93.1 M-1. The weak binding affinity 
between the CRD of LMAN1 and its ligand dimannose can be reasoned by the logic 
that tight binding between LMAN1 and its cargo might affect the release of cargo in 
the ERGIC. 
 In vivo LMAN1 always exists as hexamers which is difficult to simulate in 
vitro. The hexameric arrangement of the CRD of LMAN1 in vivo might lead to an 
additive effect on the binding affinity for the ligand. Moreover, VIP36 another 
member of the lectin family which exists as monomer and binds its ligand in the 
Golgi has weak affinity towards its ligand (high mannose glycans) but still plays an 
efficient role in post ER quality control. So it seems rational that the binding affinity 
between the CRD of LMAN1 and dimannose even though weak would be efficient 
enough for the transport of the cargo. The exact arrangement of hexameric LMAN1–
MCFD2 and cargo is yet to be solved, which would provide a better understanding.  
The reason why we used mannose α (1-2) mannose as the ligand for the CRD 
that we purified can be explained by figure 28. Here we can see that the terminal 
mannoses are linked by α(1-2) glycosidic bond and the α(1-3) linkage is located 
deeper inside the chain of glycan moiety. By frontal affinity chromatography, it was 
detected that VIP36, which belongs to the same family as LMAN1 has specificity for 
the D1 arm (figure28) (Satoh T et al, 2007). So it is likely that the CRD of LMAN1 
which shares homology with the CRD of VIP36 would display a similar behavior, 
specifically for the terminal mannoses linked by α(1-2) bond. Hence, 2α-mannobiose 
served as the ligand for our experiments on CRD. Moreover, the different di and tri 
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mannoses with α (1-3) or α (1-6) linkage are commercially not available and are 
difficult to synthesize in laboratory setup. 
 
 
3.3.3 Titration of the purified CRD with 2α-mannobiose at different saturation 
level of the CRD with Ca2+ by ITC assay 
We know that the lectin activity of LMAN1 is Ca2+ dependent. Hence any loss 
of calcium or decrease in interaction of the CRD with Ca2+ can initiate the release of 
the cargo. Since LMAN1 recycles between ERGIC and ER, it can be said that the 
release of cargo takes place in the ERGIC which is suggestive of the fact that ERGIC 
may have a lower Ca2+ concentration compared to ER. The Ca2+ concentration in the 
ER is 0.4 mM and 0.3 mM in Golgi but in ERGIC it remains undetected. It is possible 
that when the CRD of LMAN1 is less saturated with Ca2+, it releases its cargo. To 
explore the effect of the change in saturation level of the CRD with Ca2+ (in the ER to 
trans Golgi network) on interaction with the ligand, we carried out two ITC assays 
which helped us to comprehend better the mechanism of cargo release by LMAN1 
(figure 29 & 30). 
Figure 28. Chemical Structure of Man9(GlcNAc)2. (Represented from 
Satoh T et al, 2007) 
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Figure 29. The ITC assay result 
when the CRD of LMAN1 
(containing 0.4 mM Ca2+) is titrated 
with 30 mM dimannose in CRD at 
pH 7.4. The top panel shows 
practically there is no heat change 
and the lower panel indicates the 
binding curve did not have a good 
fit. 
Figure 30. The ITC assay result 
when the CRD of LMAN1 
(containing 2 mM Ca2+) is titrated 
with 30 mM dimannose at pH 7.4. 
The top panel shows significant heat 
change and the lower panel 
indicates the binding curve had a 
better fit.  
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Since the molar ratio in any ITC experiment is the ratio of the ligand to the 
macromolecule, from figure 26, it is evident that at molar ratio 2, the Ca2+ 
concentration interacting with the CRD is 0.4 mM and at molar ratio 7, the Ca2+ is 1.4 
mM. When the molar ratio is 2, it can be said by comparing the peak heights that 
about 50% of the calcium binding sites of the CRD are saturated with the ligand 
whereas at molar ratio 7, the system has reached a steady state with no further heat 
exchange suggesting that there is almost 100% saturation of the calcium binding sites 
of the CRD.  So for the ITC assays shown in figures 29 & 30, we used 0.4 mM and 2 
mM Ca2+ (little more than 1.4 mM to attain 100% saturation) in the purified CRD 
sample to titrate it against 30 mM of dimannose. It is obvious from figure 29, that 
when 50% of the calcium binding sites of the CRD were occupied, the binding 
affinity between CRD and dimannose is extremely weak (Ka = 0.0469 M-1). 
Practically no binding took place between the two molecules. However, when 100% 
of the calcium binding sites of the CRD were occupied, the binding affinity between 
the CRD and dimannose increases (Ka =71.2 M-1) (figure 30) and is similar to what 
we observed in figure 27. So from these two data it can be concluded that the CRD 
saturation with Ca2+ plays a significant role in the interaction between the CRD and 
its ligand dimannose. Lowering of Ca2+ can trigger the release of cargo by LMAN1 in 
the ERGIC.  
Even though there is a Ca2+ gradient across the anterograde secretory pathway, 
the descent is likely to be subtle. There can be possibly other factors contributing to 
the cargo release mechanism.  
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3.3.4 Effect of pH on the Ca2+ binding affinity of the CRD 
It is known that there is a progressive acidification in the organelles in 
anterograde pathway; ER has a neutral environment of pH 7.4 with lowering of pH as 
we proceed to trans Golgi network. To investigate the effect of dropping of pH on the 
calcium binding affinity of the CRD, we used the ITC assay to titrate the purified 
CRD with Ca2+ at three different pH levels – 7.4, 6.5 and 6 as a representation of the 
milieu of ER, cis-Golgi and trans Golgi network (figures 31,32 & 33 respectively). It 
was earlier hypothesized by Hauri et al (2004) that there is pH induced Ca2+ loss 
which initiates the release of cargo by the CRD of LMAN1 but there existed no direct 
evidence. From our ITC assay results (figures 31, 32 & 33) we observed that with the 
lowering of pH, the binding affinity (KB) of the CRD to Ca2+ undergoes slight but not 
significant change suggesting that there would not be any major Ca2+ loss. Hence the 
earlier model stating the pH induced Ca2+ loss being the reason for cargo release was 
not accurate.    
 
Figure 31. The ITC result from 
titration of the CRD monomer with 2 
mM Ca2+ ion at nearly neutral pH 7.4 
simulating the local microenvironment 
of ER. Binding constant (Ka) is 3.06 
*104 M-1. 
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Figure 33. At acidic pH of 6.0 
which reproduces the 
environment at Golgi, when 
the CRD monomer is titrated 
with 2 mM Ca2+, the Ka is 
even lower, it is 1.73*104 M-1 
Figure 32. The ITC result from 
titrating the CRD monomer 
with 2 mM Ca2+ ion at slightly 
acidic environment of pH 
6.5.This mimics the environment 
at ERGIC in vitro. Ka is 2.19*104 
M-1. 
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We also checked the effect of pH on the binding affinity of the CRD to 
dimannose by the ITC assay (data not shown). It was observed that lowering in pH 
has no substantial effect on the binding affinity of the CRD towards its ligand. 
Though from these ITC assays it can be precisely inferred that Ca2+ concentration 
gradient across organelles in the anterograde pathway is the sole factor contributing to 
the release of cargo by the CRD of LMAN1 but it is certainly a crucial factor in the 
release mechanism; more decisive evidence would be to check if the LMAN1-
MCFD2 complex is impervious to the Ca2+ saturation gradient of the CRD of 
LMAN1 that we used for our studies as oppose to the CRD- dimannose complex. 
LMAN1-MCFD2 should exist as a complex even at low concentration of 
Ca2+ (implying lower saturation level of the CRD with Ca2+) which otherwise 
triggered the release of cargo.  
3.4 Crystal structure of the CRD of LMAN1 bound to mannose α (1-2) mannose 
[commercially 2α mannobiose] 
With the help of molecular docking, our lab came up with an in silico model 
of the CRD of LMAN1 (data not shown) which predicted the presence of two 
potential mannose binding sites on the surface of the CRD. The molecular modeling 
technique also suggested some conceivable amino acid residues (R90 along with 
previously hypothesized N156 and D121 in the first site and S189 and Q191 in the 
second site) involved in interacting with the cargo and those residues (R90, S189, 
Q191) were located far from the Ca2+ binding site. According to the in silico model, 
mutation of these potentially critical amino acids would not disrupt the Ca2+ binding 
site unlike N156/D121, the two possibly vital amino acids involved in interaction with 
the glycoproteins and lying in close proximity to the Ca2+ binding site (Itin C et al, 
1995). Though the crystal structure of the CRD of LMAN1 was solved earlier 
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(Velloso et al, 2003) it had no ligand bound to it.  So it was absolutely necessary for 
us to solve the crystal structure of the CRD of LMAN1 bound to its ligand dimannose 
that would help us to elucidate the number of cargo binding pocket(s) of the CRD and 
the key amino acid residues involved in binding to the ligand.  
In collaboration with Dr. Saurav Misra’s laboratory at Lerner Research 
Institute, Cleveland Clinic, the crystal structure of CRD bound to mannose-α(1-2)-
mannose was solved. The functional CRD of LMAN1 that we purified was used for 
the X-ray crystallography. The resolution of the structure was 2.42 Ǻ and it revealed 
that the ligand 2α mannobiose was localized on one site involving amino acids S-88, 
H-178, F154, G 251/252, N156 and D121 (figure34) and it does not involve the 
amino acid residues (R90, S189 & Q191) predicted by the molecular modeling study. 
As observed in figure 34, the crystal structure of the CRD of LMAN1 bound to 
mannose α(1-2) mannose (dimannose) also provided us information about the 
orientation of the ligand as it fits into the ligand binding pocket. From the optical 
density of the crystals, it seemed logical that the mannose residue at n-1 position fits 
into the sugar binding pocket while the terminal mannose residue (n) lies outside of 
the pocket. Hence our crystal structure of the CRD of LMAN1 bound to ligand 
mannose α(1-2) mannose clears the ambiguity about the number of ligand binding 
pocket on the surface of CRD and shows the important amino acids involved in 
binding to the ligand. We also tried to crystallize the CRD with mannose α(1-3) 
mannose and mannose α(1-6) mannose but those crystals did not diffract any x rays.  
 
 
 
73 
 
 
 
  
Figure 34. (A) Crystal Structure of CRD of LMAN1 bound to ligand Mannose α(1-2) mannose. 
(B) The key amino acids involved on the surface of CRD involved in binding with the ligand. 
The terminal mannose of the ligand is “n” and the mannose joined to the terminal one by α (1-
2) glycosidic bond is the “n-1” mannose. (C) Enlarged photo of the ligand showing α 1-2 linkage 
between the “n” & “n-1” mannose. The carbon molecules are numbered 1-6.  (D) Zoomed 
image showing the interactions between the key amino acid residues and the ligand (shown in 
green and red). S88 interacts with the terminal mannose (n) whereas other residues (D121, 
F154, N156, H178 and G251/252) interact with (n-1) that lies within the pocket.  
Calcium ions are shown in brown, ligand shown in blue and red in A, B and C. 
A 
B 
C 
D 
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3.4.1 Comparison of the different crystal structures of the CRD of LMAN1  
 
 
 
 
 
 
 
If we compared the ligand bound state of the CRD of LMAN1 to that of 
unbound state (figure35A), apparently there was no dramatic conformational changes 
involved as both the structures were solved in presence of calcium. The structures 
Figure 35. A. Overlaying the ribbon model of the CRD of LMAN1 bound to Ca2+ (Velloso et al, 
2003; shown in green) on the CRD of LMAN1 bound to ligand mannose α (1-2)mannose and 
Ca2+(shown in grey). B. Overlay of CRD of LMAN in absence of Ca2+ (Velloso et al, 2002; 
shown in cyan) on the CRD of LMAN1 bound to ligand mannose α (1-2)mannose in presence 
of Ca2+(shown in grey). C Superposition of the three crystal structures showing no dramatic 
conformational changes in the structures solved in presence of calcium except in Loop 1 and 
Loop2 in the structure in absence of calcium. Calcium ions are shown in brown and the ligand 
shown in blue sticks.  
A B 
C 
Mannose α(1-2)  mannose 
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were superposed on one another using Pymole software; it seemed like one structure 
was aligned to the other quite well. However, the structure of the CRD bound to 
ligand when overlaid on the CRD of LMAN1 solved in absence of Calcium 
(figure35B), we saw that the loop 1 and loop 2 were not completely aligned 
(figure35C). Loop 1 remained unstructured in absence of calcium and loop 2 unfolds 
in presence of calcium. Except these changes there were no other significant 
variations in the crystal structures of CRD of LMAN1 in ligand bound and free state 
as well as calcium bound and free state. 
3.4.1.1 Comparison of the CRD of LMAN1 with the CRD of VIP36 
VIP 36 (vesicular-integral protein) also known as LMAN2 is of 36 KDa and 
belonging to the family of leguminous L type lectin. As both the proteins are 
members of the same family, the carbohydrate recognition domain (CRD) of VIP36 
shares 46% homology with the CRD of LMAN1. Despite the similarity in the core 
structure, there are some significant functional and structural differences. VIP36 is 
glycosylated whereas LMAN1 is nonglycosylated (Kamiya Y et al, 2008). The CRD 
of VIP 36 binds to one Ca2+ rather than two like the CRD of LMAN1 and there is no 
evidence on oligomerization of VIP36 whereas LMAN1 exists as homo hexamers. 
VIP36 lacks the helical domain of LMAN1. The crystal structure of the CRD in Ca2+ 
bound state of VIP36 was initially solved using the Ca2+ bound CRD of LMAN1 as a 
model. But later on, structure of the ligand bound form of the CRD of VIP36 in 
presence of Ca2+ was revealed by Satoh T et al in 2007. Our structure of the CRD of 
LMAN1 bound to its ligand when superimposed on the CRD of VIP36 bound to 
mannose using Pymole software we observed no major deviations (figure33D); 
though some minor structural differences were observed in loop 1(loop 1 of VIP36 is 
longer by two amino acids) and loop 3 of VIP36 and LMAN1 and side chain 
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orientation of few amino acid residues are different between the two lectins 
(figure36). The amino acid residues of LMAN1 involved in binding to ligand are 
somewhat similar to that of VIP36 (Satoh T et al, 2007). Even the orientation of the 
ligand was same in both the proteins. LMAN1 acts as a cargo transporter binding its 
cargo in the ER at a neutral pH of 7.4 and releasing the cargo in ERGIC but the 
optimum pH required for ligand binding by VIP 36 is 6.5. VIP36 binds its cargo in the 
Golgi, dependent of Ca2 + and evidences indicate the main function of VIP 36 is post 
ER quality control, recognizing and recycling incompletely folded, untrimmed 
proteins back to ER. In spite of the resemblance that we observed from the 
superposed model (Figure 36), the functional differences of the two proteins are 
noteworthy.  
 
  
Figure 36. A. Shows the overlay of 
ribbon model of CRD of VIP36 on 
CRD of LMAN1.  B. Magnified view  
of the ligand binding site in the 
ribbon model comparing  the crystal 
structure of CRD of VIP36 (shown 
in yellow) bound to ligand mannose 
α 1-2 mannose (shown in teal) and 
CRD of LMAN1 (shown in grey) 
bound to mannose α(1-2) mannose 
(shown in teal blue).  Both the 
structures solved in presence of 
Calcium (brown sphere) and aligned 
well with each other without any 
major variation.  
Loop1 
Loop2 
A 
B 
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3.5 Mannose binding assay  
The crystal structure of the CRD with mannose α (1-2) mannose revealed the 
amino acids that are involved in interaction with the ligand. But it was necessary to 
determine the most critical amino acids from this group whose mutation would lead to 
abolishment of mannose binding by the CRD of LMAN1. So we carried out mannose 
binding assay with the mutants and the wild type plasmid.  The mutants used for this 
purpose were S88A, F154Y, H178A and G251A/252A.  
 
 
 
 
From Figure 37, it is evident that H178A mutant and G251A/252A double 
mutant has the most prominent effect of mannose binding. The intensity of the band 
was extremely weak for these mutants. So it can be inferred that these two amino 
acids on the surface of the CRD are most critical for binding to mannose and mutation 
in these residues leads to abolishment of the ability to interact with cargo 
glycoproteins.  
It has earlier been observed that mutation in H-178 obliterated mannose 
binding (Hauri et al, 2004) but then it was not known if H-178 interacted with the 
Figure 37. Result from the western blot with anti-flag antibody performed after mannose 
binding assay of the mutants and the wild type (WT) plasmids. The first six lanes are the 
samples before dialysis which served as the loading controls to check the level of protein 
expression by each plasmid when transfected into COS1 cells. 
Cell lysate Elution Samples 
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ligand. Our crystal structure showed that H-178 has direct interaction with the ligand. 
Moreover it was earlier found that H178 was the only basic amino acid on the surface 
of CRD. So it was hypothesized that this residue might act as a “proton sensor” 
detecting change in pH levels as the CRD of LMAN1 translocate the cargo proteins 
from ER to ERGIC and thereby trigger the release of cargo in the ERGIC (Hauri H-P 
et al, 2004). However, our in-vitro studies showed that mannose binding of the CRD 
is not dependent on pH levels. H-178 and G251/252 are the amino acids interacting 
with the mannose residue at “n-1” position and mutation in them disrupts the sugar 
binding site. F154 is another amino acid interacting with this residue but perhaps 
mutation in F-154 may not lead to obliteration of enough hydrogen bonds with the 
mannose and hence it does not lead to abolishment of sugar binding. 
3.6 Purification of MCFD2 
Cellular MCFD2 is always bound to LMAN1 in a 1:1 stoichiometry (Zhang B 
et al, 2005). The precise role of MCFD2 is unclear; it may affect the sugar binding 
ability of LMAN1 or play other important roles in the cargo capture and release 
process. Because it is essential for LMAN1-MCFD2 complex formation, we would 
like to check the integrity of LMAN1-MCFD2 complex at different conditions 
mimicking the milieu of ER, ERGIC and Golgi.  
For biochemical experiments, we need purified MCFD2. By using the 
principle of IMAC (immobilized metal affinity chromatography), we purified MCFD2 
by passing the crude cell lysate through the Ni-NTA resin packed in a column, 
followed by overnight digestion with thrombin to remove the His tag. Finally non-
specific proteins were removed by Superdex 75 column (Figure 38) [details in 
Chapter 2]. Peak 1(P1) of Figure 38 is the peak of MCFD2. It is eluted at a position 
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equivalent to a dimer as reported previously (Kawasaki N et al, 2008). Each of the 
fractions collected by chromatographic purification was electrophoresed on a SDS gel 
(Figure 39).  From the coomassie stained gel picture (Figure 39), it is evident that P1 
is MCFD2 (MW 16KDa), running close to MW ~ 17KDa of the protein ladder.  With 
the purified MCFD2 we would try to check if the binding ability of LMAN1 towards 
its ligand increases in the presence of MCFD2. 
 
 
Figure  38. Chromatogram from Superdex 75 gel filtration chromatography of MCFD2 sample 
which was eluted from Ni-NTA column and digested with Thrombin overnight at 4°C. P1 
fraction is the target protein MCFD2 after we compared the retention time and volume with that 
of protein standard.  
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It has been demonstrated earlier that the soluble form of LMAN1 bound 
modified surface glycans of HeLaS3 cells only in the presence of wild type MCFD2 
and Ca2+ (Kawasaki N et al, 2008). However, X-ray crystallography revealed that 
MCFD2 binding site on LMAN1 is distant from the sugar binding site and the 
LMAN1-MCFD2 complex formation is impertinent to sugar binding (Nishio et al, 
2010). To clarify the role, if any, of MCFD2 on the ligand binding affinity of LMAN1 
we would like to compare the LMAN1 sugar binding ability in the presence or 
absence of MCFD2 by the ITC assay under physiological conditions. Being a soluble 
cofactor of the cargo receptor complex, MCFD2 is likely involved in other roles in the 
capture and release process of the cargo proteins. Biochemical experiments would 
help us to elucidate its functions. 
 
P2 P3 
62 
49 
38 
28 
14 
17 
KDa 
Figure 39. The fractions 
that were collected from 
Superdex 75 purification 
was electrophoresed and 
stained with Coomassie. 
The MW of the P1 
fraction on the gel when 
compared to protein 
ladder matched with the 
MW of MCFD2 
(16KDa). 
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CHAPTER IV 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
4.1 Conclusions 
Using our developed protocol of denaturation and refolding, we were able to 
purify the CRD monomer of LMAN1 to study the structural basis for LMAN1 cargo 
capture in the ER and release in the ERGIC. Using the ITC assay, we demonstrated 
that the purified CRD was able to bind two Ca2+ ions, which is consistent with earlier 
reports that the CRD of LMAN1 has 2 Ca2+ binding sites. This indicated that the 
purified protein retained its functionality. This ITC assay also revealed the binding 
affinity of the CRD with Ca2+, which is of moderate intensity (KB=104 M). Thus our 
denaturation refolding strategy worked well for our target protein. The purified and 
functional CRD was used for X-ray crystallography to obtain the ligand bound 
structure of the CRD. The X-ray crystal structure of the CRD that was solved in 2003 
had no ligand bound to it. Uncertainties existed on the specific location, number of the 
binding sites and the key amino acids involved in ligand binding. The ligand for 
LMAN1 and its correct orientation facilitating a proper fit into the receptacle on the 
CRD was ambiguous. Based on information from published results, physiological 
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rationale and easy availability, we decided to use mannose α (1-2) mannose as the 
ligand for LMAN1 in our in vitro studies.  Mannose α (1-2) mannose mimics the 
terminal structure of glycan moiety where the mannose at the “n” position is linked to 
mannose at “n-1” position by a glycosidic bond. From our solved crystal structure of 
the CRD with its ligand dimannose, it appeared that the ligand mannose α (1-2) 
mannose fits properly into the ligand binding pocket. The crystal structure also helped 
us to know the correct orientation of the ligand, the mannose at the “n-1” position lied 
within the pocket while the mannose at “n” position branched out. We were also able 
to decipher the key amino acids involved in interacting with the dimannose on the 
side chains of the cargo molecule. The key amino acids involved include S88, D121, 
N156, F154, H178 and G251/252.  From the crystal structure it was evident that there 
is one mannose bound to the surface of the CRD of LMAN1. The amino acids 
involved in networking with the carbohydrate moiety were tested further by 
mutagenesis studies and in vivo experiments to confirm their significance in 
interaction with the sugar residues. Mannose binding assay was performed with the 
wild type LMAN1 and mutants - S88A, F154Y, H178A and G251A/252A. It was 
observed that H178 and G251/252 are most critical for mannose binding and 
mutations in these residues led to complete abolishment of the binding ability of the 
CRD to its ligand.  
Apart from solving the crystallographic structure of the CRD bound to 
dimannose, we were also successful in determining the binding affinity of the CRD to 
its ligand. From our experiments, the binding between the CRD and its ligand 
mannose α (1-2) mannose is weak, which might be required to facilitate the easy 
release of cargo at the ERGIC. To elucidate the mechanism of cargo release by 
LMAN1, we checked the effect of pH on the binding affinity of the CRD to Ca2+ ions 
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by the ITC assay. It was observed that the binding affinity (KB) between the CRD of 
LMAN1 and Ca2+ did not decrease significantly with the decrease in pH. Also the 
lowering of pH had no effect on the binding affinity between the CRD and the 
dimannose. However, we noted that the saturation level of the CRD with Ca2+ played 
a significant role in the binding affinity of the CRD with its ligand. When we titrated 
the CRD with dimannose at different Ca2+ concentrations, we observed that at a lower 
saturation level of the CRD (Ca2+ at 0.4 mM, 50% sites of the CRD saturated with 
Ca2+); there is practically no binding between the CRD and its ligand. When the Ca2+ 
concentration in the CRD is increased to 2 mM (100% of the sites of the CRD 
saturated with Ca2+), the binding affinity of the CRD for dimannose increased 
significantly.  
We know that the lectin activity of LMAN1 is Ca2+ dependent and there is a 
progressive acidification of the organelles from the ER to the Golgi. LMAN1 binds to 
its cargo FV/FVIII in the ER, which is at relatively neutral pH of 7.4. The cis and 
trans Golgi network have a pH range from 6.7-6.0.  The Ca2+ level in the ER is 0.4 
mM and in the Golgi it is 0.3 mM. The pH and Ca2+ levels of the ERGIC where the 
cargo release takes place is not known, although an earlier study reported an 
undetectable level of Ca2+. Lower Ca2+concentration in ERGIC decrease the affinity 
of LMAN1 with cargo and this trigger the release of cargo. Our results support a 
model in which the relative saturation level of the CRD with Ca2+ plays the crucial 
role in the cargo release by LMAN1.  
From our results, it is evident that Ca2+ concentration affects only the 
interaction between LMAN1 and the cargo. The interaction between LMAN1 and 
MCFD2 is much stronger (Ka in the range of 107-108 M-1) and is less sensitive to 
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changes in pH and Ca2+ concentration ensuring the integrity of the LMAN1-MCFD2 
receptor complex during the cargo release process (Kawasaki et al, 2008).  
 
 
4.2 Future Directions 
The crystal structure predicts that both the H-178A and G251A/252A abolish 
mannose binding without altering Ca2+ binding. To confirm that these mutants retain 
full Ca2+ binding capacity, we will purify these two mutant proteins and test their 
Ca2+ binding by the ITC assay. To do this we need to create new mutant constructs in 
the backbone of pET15b vector and express the corresponding protein products. 
These mutant proteins will be then purified by Superdex 75 column and titrated 
against Ca2+ in an ITC experiment. If the mutants show no significant change in the 
binding affinity for Ca2+ as compared to the WT CRD construct (the protein that we 
used for our ITC experiments), then it can be concluded that point mutations at H-178 
and G251/252 disrupt the mannose binding ability of the CRD only, without 
disrupting the Ca2+ binding site. These mutant proteins can also be tested by the ITC 
assay to confirm their inability in binding mannose. We do not expect to observe any 
interaction when the mutant proteins would be titrated with dimannose.  
To support our proposed model, that only Ca2+ concentration gradient is 
crucial factor contributing to the release of cargo by LMAN1, we would titrate the 
purified CRD against purified MCFD2 at different saturation levels of the CRD with 
calcium to ensure the stability of the LMAN1-MCFD2 complex across different 
levels of calcium. We expect to observe a strong affinity between the CRD and 
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MCFD2 or no significant change in Ka between the CRD and MCFD2 at the same 
saturation levels of the CRD with Ca2+ which affected the Ka between the CRD and 
dimannose ; thereby helping us to conclude that it is only the binding affinity between 
the LMAN1 and the ligand which gets affected by change in calcium concentration 
while the LMAN1-MCFD2 complex remains insensitive to this change. 
In the in vivo and in vitro mannose binding assays we examined the effects of 
LMAN1 mutations on their binding to the dimannose, equivalent to the terminal 
mannoses of the glycan moiety attached to glycoproteins. As stated above, these 
mutations are predicted to affect mannose binding without disturbing the calcium 
binding. FV and FVIII are the known glycoprotein cargo of LMAN1 responsible for 
the pathology of F5F8D. Next we would like to check whether mutations in LMAN1 
that abolish mannose binding will also abolish FV/FVIII binding. Failure of mannose-
binding mutants to interact with FV/FVIII would indicate that the role of calcium in 
LMAN1 is to hold the mannose binding pocket together.  
To test binding ability of LMAN1 mutants on the actual cargo proteins, COS I 
cells will be cotransfected with the Flag tagged WT or mutant LMAN1 (H178A or 
G251A/252A) and FV/FVIII. Twenty hours after transfection, cells will be 
metabolically labeled with [35S]-methionine/cysteine for 45 minutes followed by a 30 
minutes incubation in complete medium. This would allow the newly synthesized 
proteins to be labeled. The cells will be then treated with a crosslinking agent [DSP 
(dithio-bis succinimidyl propionate)] which will covalently link two interacting 
proteins. The interactions between LMAN1 and FV/FVIII will be assessed by 
immunoprecipitation using anti-Flag, anti -FV or anti-FVIII antibodies. If mannose 
binding activity of LMAN1 is important for interaction with FV/FVIII, in the 
presence or the absence of cross-linker because FV/FVIII will not be precipitated 
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along with mutant flag tagged LMAN1, using an anti-flag antibody. The WT flag 
tagged LMAN1 should show positive signal for FV/VIII by anti-flag antibody as WT 
LMAN1 would be able to interact with FV/FVIII and precipitate together.  
The other study that we intend to do is to create a construct of LMAN1 with 
both the CRD and the helical domain (the entire luminal domain along with conserved 
cysteine residues C466 and C475) in a pET15b vector, express it into BL21 cells to 
have the corresponding protein. This protein would be then purified by modifying our 
denaturation-refolding protocol and used for crystallization to obtain the structure of 
the oligomerized LMAN1-MCFD2 complex. This structure will reveal how individual 
subunits of LMAN1 and MCFD2 are arranged in the hexamer. FV and FVIII are both 
large proteins containing multiple N glycosylation sites. It is important to figure out 
whether adjacent subunits of LMAN1 can coordinate to bind different branches of the 
same N-linked glycan or different oligosaccharides. Our lab has demonstrated that 
both LMAN1 and MCFD2 can interact with FV/ FVIII (Zheng C et al, 2010a). The 
oligomeric structure of the LMAN1-MCFD2 complex will shed light on how FV and 
FVIII cargo proteins simultaneously (or sequentially) interact with both MCFD2 and 
LMAN1.  
In order to elucidate the role of MCFD2 on carbohydrate binding by the CRD 
of LMAN1, we need to first confirm that the purified MCFD2 is functional. This will 
be done by the ITC assay. It is known that LMAN1 and MCFD2 exist in a 1:1 
stoichiometric complex. In this calorimetric assay the purified CRD is titrated against 
the purified MCFD2 in presence of Ca2+ using 10 mM Hepes and 150 mM NaCl at 
almost neutral pH of 7.4. If the stoichiometry of binding (n) is 1, this would indicate 
that the purified proteins are fully functional. If the purified proteins were non-
functional then they would not be able to bind to one another in the 1:1 ratio. The 
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functional proteins are then allowed to form a complex in vitro and the complex will 
be purified by gel filtration chromatography to remove any unbound proteins. The 
purified complex will then be titrated against mannose α 1-2 mannose (ligand) and the 
association constant or Ka between the two is determined by the ITC assay. This Ka is 
compared with the Ka between the purified CRD (which is not complexed with 
MCFD2) and mannose α (1-2) mannose. If the Ka value is not higher when the CRD 
is bound to MCFD2, then it is likely that MCFD2 does not enhance the sugar binding 
ability of LMAN1.  
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APPENDIX 1 
 
1. Construction of pET15-GST-CRD 
Restriction Digestion of pET15b-CRD with NCoI (50µl reaction) 
Water Vector(pET15b-CRD) NE Buffer 3 Nco1 
8 µl 35 µl 5µl 2 µl 
  
Restriction Digestion of Amplified GST (insert) with NCoI (50µl reaction) 
Water Vector(pET15b-CRD) NE Buffer 3 Nco1 
8 µl 35 µl 5µl 2 µl 
 
Ligation Reaction 
Water Ligation 
Buffer (2X) 
Vector(pET15bCRD) Insert(GST) Ligase 
1 µl 5 µl 2 µl 1 µl 1 µl 
 
Restriction Digestion of pET15b-GST-CRD with NCoI (20µl reaction) 
Water Ligated Plasmid(pET15b-GST-CRD) NE Buffer 3 Nco1 
12.5 µl 5 µl 2 µl 0.5 µl 
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APPENDIX 2 
Construction of pET15-CRD 
Restriction Digestion of Amplified CRD (insert) with Nde1 & BamH1 (50µl reaction) 
Water Amplified 
CRD 
NE Buffer 
3 
BSA BamH1 Nde1 
7.5 µl 34 µl 5 µl 0.5 µl 1.5 µl 1.5 µl 
 
Restriction Digestion of pET15b (vector) with Nde1 & BamH1 (50µl reaction) 
Water Vector NE Buffer 
3 
BSA BamH1 Nde1 
7.5 µl 34 µl 5 µl 0.5 µl 1.5 µl 1.5 µl 
 
Restriction Digestion of Ligated pET15b-CRD with NdE1 & BamH1 (20µl reaction) 
Water Amplified 
CRD 
NE Buffer 
3 
BSA BamH1 Nde1 
11.8 µl 5 µl 2 µl 0.2 µl 0.5 µl 0.5 µl 
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APPENDIX 3 
3. Crystallization and data collection 
Crystals of FlnA-Ig10 were grown by hanging drop vapor diffusion at 293 K 
in 2 µl drops. Sitting drops initially in a 1:1 ratio mixture. Final hanging drops in a 2:1 
(protein: screen) ratio mixture (1.2 µl drops) 
Hanging drops consisted of a 1:1 ratio mixture of 1 mM (10 mg/ml) protein 
and a reservoir solution. Initial screening was conducted using the sparse matrix 
crystallization screens JCSG+ (Qiagen), ProComplex (Qiagen), Classics (Hampton 
Research), Index (Hampton Research) and SaltRx (Hampton Research). Subsequent 
optimizations identified an optimal reservoir solution composed of 0.2 M ammonium 
acetate, 25 %( w/v) polyethylene glycol (PEG) 3350 and 0.1 M Bis-Tris, pH 5.5. 
Single crystals appeared after 6 weeks and grew for an additional 2 weeks. Crystals 
were cryoprotected by brief transfer through reservoir solution supplemented with 
20% (w/v) glycerol and flash-frozen in liquid nitrogen. 
 Diffraction data was collected with a Cu-Kα source at 1.5418 Å using a 
Rigaku MicroMax-007HF generator and a Rigaku Saturn 944+ CCD detector. Data 
integration was performed with XDS (2). Data reduction and scaling were performed 
with SCALA (3). The final data set was processed to a cut-off of 2.44 Å, based on 
significant drops in unaveraged I/sigma (<2.7) and completeness (<90%) in shells at 
higher resolutions. 
 
Structure solution and refinement 
97 
 
A molecular replacement search model was generated by iTASSER using the 
HsFlnA-Ig10 sequence (residues 1158-1252) as input. Phases were calculated by 
molecular replacement using the PHASER component of PHENIX. The best 
molecular replacement solution was subjected to automated rebuilding in PHENIX 
with RESOLVE, followed by iterative rounds of model building in COOT and 
refinement in PHENIX. The refinement protocol used isotropic atomic displacement 
parameters for all atoms. All molecular structure figures were generated with Pymole. 
Validation and deposition 
Stereochemical analysis of the FlnA-Ig10 structure was completed with MolProbity. 
All residues are within the favored regions of the Ramachandran plot. No poor 
rotamers or Cβ deviations were found. MolProbity analysis of all-atom contacts 
calculated a clash score of 7.09, which ranks the FlnA-Ig10 structure in the 98th 
percentile of 326 structures deposited in the PDB that were solved at similar 
resolution (2.442 Å ± 0.25 Å). The MolProbity score, a weighted measure of 
stereochemical statistics, was 1.44, which ranks the FlnA-Ig10 structure in the 100th 
percentile of 7,752 structures of similar resolution deposited in the PDB. The atomic 
coordinates for Ig10 have been deposited in the PDB (accession code XXX). 
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APPENDIX 4 
 
pED vector Map (Kaufman R, Molecular biotechnology, Vol16, 2000) 
 
 
 
 
 
